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Abstract 
 
Background: The menopausal transition may affect women’s quality of life. Hormone 
therapy (HT) has been shown to be effective in alleviating menopausal symptoms, such as hot 
flashes. The age at natural menopause (ANM) is of clinical relevance since earlier menopause 
is associated with increased morbidity and mortality. It is therefore important to identify 
means to ensure a healthy menopause. More than a decade ago HT use rates plummeted, 
however the current situation on its use is unclear. Factors associated with ANM and HT use 
vary across populations; little is known on such factors in Canada. Obesity after middle age 
has deleterious health consequences; yet the relationship between absolute and relative 
weight, BMI and waist circumference (WC), and ANM is inconclusive. 
Objectives:  1) To investigate the role of changes in anthropometric measures on ANM. 2) To 
elucidate factors associated with ANM in Canada, and 3) to examine the prevalence and 
characteristics of HT use. 
Methods: To answer objective 1, data from the Coronary Artery Risk Development in Young 
Adults (CARDIA) study were used. To answer objectives 2 and 3, secondary data analysis 
was conducted on baseline data from the Canadian Longitudinal Study on Aging (CLSA).  
Multinomial logistic, and Cox Proportional hazard regressions were performed. 
Results: Baseline WC and > 5 % loss of baseline weight were modest predictors of ANM in 
middle-aged women. Premenopausal hypertension and blood pressure indicators were also 
significantly related to an earlier ANM. Median ANM was 51 years. Having no partner, low 
household income and education levels, current and former smoking, and cardiovascular 
disease (CVD) were associated with an earlier ANM, while current employment, alcohol 
consumption, and obesity were associated with later ANM. Current HT use was 9.5%. Older 
age, non-white ethnic background, current employment, regular smoking, obesity, and breast 
cancer were negatively associated with current HT use. Alcohol consumption and presence of 
allergies or mood disorders were positively associated with current HT use. 
Conclusion: Menopausal age is in part determined by modifiable factors. These findings may 
be used to inform opportunities regarding menopause management, and help in prevention, 
assessment, and early management of chronic disease risk during the menopausal transition. 
 
Keywords: Age at Menopause, Hormone Therapy, Canada, Factors, Obesity, Aging 
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Chapter 1 
 
General Introduction 
Biology of Menopause 
The female adult life cycle can be divided into premenopausal, perimenopausal 
(menopausal transition), and menopausal (postmenopausal) phases1. Follicles are the functional 
units of the ovary that each contains an oocyte and its surrounding granulosa cells. These 
follicles are necessary for fertility and constitute a woman’s “ovarian reserve” which is formed at 
birth1. Given that a woman is born with an exhaustible and non-replenish-able supply of oocytes, 
the peak number of follicles attained in utero or at birth have a major contribution to the age of 
menopause2.  The number of follicles peaks at approximately 5 million before birth but then 
declines to around 2 million at birth. The high rate of loss continues throughout the pubertal 
years such that only 300,000-400,000 oocytes remain at puberty at which time the rate of loss 
slows until hormonal changes along with genetic and environmental exposures interact to 
transition into menopause3, 4.  
 
Definition of Age at Natural Menopause (ANM) 
According to the World Health Organization (WHO) 5, natural menopause is defined as at 
least 12 consecutive months of amenorrhea not due to surgery or any obvious cause. Natural 
menopause results from the loss of ovarian follicular function and atresia3 and is reached when a 
woman’s follicular reserve is depleted to approximately 1000 follicles. Therefore, reproductive 
aging in women is characterized by a decline in both the quantity and quality of oocytes. Several 
studies emphasize the major individual variability on the extent of follicle pool depletion during 
life6.  Numerous studies revealed a considerable variation in the age at menopause both within 
and between populations7-15, approximately 40% to 60% of which is genetically determined 16-18. 
Physiological sources of variation in age at menopause include the original number of oocytes 
and the rates of atresia19-20.  
 
Outcomes of ANM 
Age at menopause has subsequent health implications for women. Later menopausal age 
increases the risk of breast, endometrial, and ovarian cancers while earlier age of menopause is a 
known risk factor for the metabolic syndrome (MetS), hypertension, cardiovascular disease 
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(CVD), atherosclerosis, stroke, autoimmune disease and osteoporosis, due to an earlier 
deficiency in estrogen3, 25, 26. ANM has also been linked to mortality with all-cause mortality 
being reduced by 2% with each increasing year of menopause27. 
 
Factors Associated with ANM 
The timing of natural menopause may also serve as a marker for reproductive aging with 
an earlier menopause indicating premature aging24. Genetic factors are key factors that influence 
menopausal age18. However, the specific genetic determinants involved remain unclear. Studies 
suggest that between 15 and 70% of the variability in age of onset of menopause is of non-
genetic origin and therefore potentially modifiable26. Environmental influences on age at 
menopause include parity, life-course characteristics, socioeconomic status and health 
behaviors21-23. However, only smoking status is consistently linked to earlier menopause3, 25, 26. 
Some studies have reported a positive association between BMI and age of onset of menopause, 
while others have not found an association26. Studies on physical activity are also inconclusive27, 
28, and the relationship between diet and onset of menopause is inconsistent. For diet, it has been 
reported that vegetarians undergo an earlier onset of menopause compared to omnivores29, yet 
others have found that high consumption of green/ yellow vegetables28, and fruit27 is associated 
with a later menopause. High fat intake was associated with a later onset of menopause in a 
German study31, yet no relationship was noted between fat intake and menopause in other 
studies27, 28.  
Chronic diseases have also been linked to menopause onset32-34. The relationship and 
direction between CVD, and its risk factors in relation to ANM is not clear, however. CVD could 
be a risk factor for ANM, due to estrogen depletion increasing cardiovascular risk35. CVD risk 
factors such as cholesterol, low-density lipoprotein cholesterol levels, and systolic and diastolic 
blood pressure levels may be associated with menopausal status, independent of age36-37.   
 
Menopause and Hormone Therapy (HT) 
Menopause is characterized by a series of clinical symptoms, such as vasomotor 
symptoms (VMS), mood disorders, and poor quality of sleep, all of which are caused by the 
decline and ultimate cessation of ovarian function38. These symptoms may significantly impair 
the quality of life of women. Hormone therapy (HT) is an appropriate and effective way to 
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relieve menopause symptoms and some long-term complications that are caused by the decline 
in endogenous estrogen, such as dyslipidemia, cardiovascular disease and osteoporosis39-41. 
However, the publication of findings from prospective studies, including the Heart and 
Estrogen/progestin Replacement Study (HERS)42 and the Women’s Health Initiative (WHI) 
Study43 raised questions about the safety of HT, particularly with regard to cardiovascular effects 
and breast cancer. The results of these studies dramatically decreased the world-wide use of HT. 
Since then, after revision of the initial findings, HT has been shown to have a complex balance 
of benefits and risks with important effects on various health outcomes, some of which differ 
according to the various hormone therapy formulations44. Few studies have investigated the 
characteristics of women who use HT. Younger age, higher educational level, postmenopausal 
status, African American and Hispanic ethnicity, and being married have been associated with 
HT use, however not all of these associations are consistent45-50. Little research has been done on 
HT use in Canada51, 52, an ethnically diverse setting where rates of use might differ between 
subpopulations. 
 
Conceptual Framework 
On average, women spend more than a third of their lifetime after the onset of 
menopause53. With the surge in aging populations worldwide, it is estimated that in the year 
2030, 1.2 billion women will be peri or postmenopausal and that this total will increase by 4.7 
million per year54.  Life events and experiences are hypothesized to have long lasting influence 
on health55. A life course perspective focuses on how the life history from birth to death of 
individuals may explain differences in health55. Moreover, the life course perspective highlights 
continuity and changes of exposures across the life span, through trajectories or patterns of 
behavior over time56-58.  It is important to note that the term life span is embedded in the life-
course perspective however; it should be distinguished from the term life course since it is seen 
as a dynamic process in which human development interacts with the social environment in a 
multilayered social and cultural context55-58. Life course epidemiology in particular, attempts to 
integrate biological risk processes occurring throughout life with disease onset risk and various 
health and developmental outcomes59, and therefore, follows the life course perspective. The 
purpose of life course epidemiology is to build and test models that modulate pathways linking 
exposures across the life course to health outcomes. According to this perspective, the event of 
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menopause cannot be separated from ongoing life prior to its occurrence60. The life course 
perspective is embedded in this project, since this framework encourages testing of the temporal 
order of exposure variables across life and their inter-relationships with the outcome. The life 
course perspective views menopause as an outcome of many internal (biological) and external 
factors that interact to control the rate of lifetime follicle loss61. Factors which operate earlier in 
life, such as early life exposures62, while others such as type 2 diabetes which operate closer to 
menopause to influence menopause onset, may be integrated within the same model. 
Specifically, if the associations of earlier factors are to be taken into account, then it is integral to 
consider other factors across life which may act as confounders or mediators of associations that 
affect menopause onset. 
 
Significance of the Dissertation 
Menopause signals the end of a female’s reproductive lifespan, and the timing of this event 
provides an indication of a woman’s reproductive and later physical health. Although age at 
menopause is a biological marker for aging in women, it is not a pathological condition. 
Therefore, ensuring means for a healthy menopause, with the term healthy indicating overall 
health from a holistic perspective60, is crucial. This dissertation aims to develop a model of the 
factors associated with HT use around the time of menopause as well as age of onset of 
menopause. Given that the rate of HT use by menopausal women has undergone significant 
changes in recent years, this dissertation also aims to obtain the prevalence of HT use in the 
Canadian context. Identifying the prevalence of HT use is important to properly understand 
whether women are abiding by the guidelines for its use. This in turn can assist in monitoring 
trends of HT use as well as in aiding future recommendations on its indications. Timing of 
menopause on the other hand, is a factor in determining total duration of internal estrogen 
exposure, which portends postmenopausal health risks. Investigating the factors associated with 
timing of natural menopause will contribute to the detection of women at high risk of developing 
these health risks. Therefore, describing the correlates of ANM may generate new strategies for 
improving women’s health, as its potential risk factors are amenable to prevention. Second, there 
is considerable variability in ANM worldwide, and by providing an estimate of the median ANM 
in Canada, this dissertation will enable international comparisons as well as monitor secular 
trends in ANM. Examination of exposures across life is essential to understanding potential 
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critical periods of susceptibility to an earlier or later menopause to identify pathways to 
menopause. Finally, by examining factors that are potential missing links to understanding age at 
menopause, this study will lend epidemiologic evidence and methodological insight on novel 
confounders for future work.
5 
 
1.1 Specific Objectives 
 
Objective (1): To assess the impact of changes in weight, BMI, and waist circumference 
across time on ANM in a sample of US women.  
 
Objective (2): To elucidate median ANM and investigate associations between various 
factors and ANM among Canadian women.  
 
Objective (3): To determine the prevalence of HT use and evaluate the associations between 
various factors among Canadian women and HT use. 
 
Data from the Canadian Longitudinal Study on Aging (CLSA) and from the Coronary Artery 
Risk Development in Young Adults (CARDIA) study were used to answer these objectives. 
The subsequent chapters will present the findings of the individual analyses done to answer the 
objectives above.  
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Chapter 2 
 
Longitudinal Changes in Weight, Body Mass Index, Waist Circumference, and Age at 
Natural Menopause in the Coronary Artery Risk Development (CARDIA) Study 
Abstract 
Objective: The age at natural menopause (ANM) has subsequent health implications. Earlier 
ANM is a risk factor for cardiovascular disease (CVD), atherosclerosis, and stroke. Despite 
extensive study, no clear and conclusive association between anthropometric measures and ANM 
has emerged. This study aims to assess whether baseline and/or longitudinal changes in 
anthropometric measures are associated with ANM. 
Methods: 2192 premenopausal women from the Coronary Artery Risk Development in Young 
Adults (CARDIA), a prospective study with 25 years follow up, were included for analysis from 
1985-1986 until menopause was attained. Anthropometry included weight, body mass index 
(BMI) and waist circumference (WC). Absolute and relative changes in anthropometric measures 
since baseline and each exam were computed. Discrete–time survival analysis was then used to 
determine the association between anthropometric measures at baseline as well as their absolute 
and relative changes with ANM, while adjusting for various time-varying and invariant 
covariates in separate models. 
Results: Multivariate Cox regression analysis showed that baseline WC (HR=0.98; 95% 
CI=0.97-0.99) significantly increased the risk of a later ANM. Neither absolute nor relative 
changes in anthropometric measures were associated with ANM with one exception. If there was 
more than 5% weight loss since baseline, the hazard rate for an earlier ANM decreased by 45% 
(HR=0.55, 95% CI=0.31-0.97). Premenopausal hypertension was strongly associated with an 
earlier ANM in the model for weight (HR=1.32; 95% CI=1.04-1.66), BMI (HR=1.32; 95% 
CI=1.05-1.68), and WC (HR=1.35; 95% CI=1.05-1.68), respectively. 
Conclusion: These findings show that ANM is partly determined by modifiable factors such as 
premenopausal hypertension and baseline WC. These results highlight the importance of both 
control and prevention of cardiovascular risk factors such as excess weight in early to mid- 
adulthood prior to menopause onset, an independent cardiovascular risk factor.  
Keywords: Menopause, Age, Risk Factors, Weight, Waist Circumference, BMI
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1.2 Introduction 
 
Age at Natural Menopause (ANM) is of clinical and public health importance as it 
represents a marker of general health and aging, given that early menopause is associated with 
higher risk of cardiovascular disease (CVD), cognitive decline, osteoporosis and premature 
mortality 1,3-8, 10-14. Despite extensive study, no clear and conclusive association between 
adiposity (weight and/or BMI) and menopausal age has emerged from the literature. Paramsothy 
et al1, using data from the Study of Women’s Health Across the Nation (SWAN), found that 
women with obesity had longer menstrual cycle lengths than women with normal weight during 
the menopausal transition. Women with longer menstrual cycles during their reproductive years 
have been shown to have a later age at menopause2. In fact, research has suggested, but not 
consistently3, 4, that a higher BMI might increase the risk of a later menopause5-7. A recent meta-
analysis found that increased BMI is moderately associated with a later ANM8; however, the 
studies included were heterogeneous in terms of their study designs and measures of weight. 
Therefore, the pooled result requires further confirmation. It is hypothesized that increased 
production of estrone (a precursor of estrogen) in the adipose tissue of women with obesity 
might contribute to a delay in their menopause9, as estrone may supplement estradiol levels. 
Estrone is formed by the peripheral aromatization of androgens, namely androstenedione, 
secreted by the ovaries and/or adrenal glands10. Obesity has been linked to more androgens being 
converted into estrone11. Therefore, increased peripheral production of estrone in women with 
obesity may contribute to the delay in age at menopause.  
 
It  is also suggested that hormonal imbalances occurring as a result of weight change 
across life increase the rate of follicular atresia12, thereby influencing the timing of menopause. 
Therefore, it may be weight change rather than absolute weight per se that influences ANM. 
However, few studies have examined the relationship between weight change across time and 
ANM. In fact, previous findings on weight gain or loss and menopausal age were also 
inconsistent, possibly because of differing methodologies, with studies across various settings 
showing either no association13,14, a positive association7,15,16 or an inverse association3,12. 
Aydin15 found that premenopausal BMI gain rate and premenopausal weight loss of more than 5 
kg were both associated with later ANM. Similarly, Dorjgochoo et al7 found a dose-response 
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relationship between midlife weight gain and later ANM. This is in contrast to Kok et al17 who 
reported both increasing and decreasing premenopausal relative weight as risk factors for earlier 
ANM. In a further study, Hardy et al13 did not find an association between both underweight or 
overweight BMI trajectories and ANM; however, BMI and age at menopause were self-reported, 
and BMI was measured from age 18 until 43 years. On the other hand, using data from SWAN, 
Gold and colleagues18 found that an increased concurrent BMI and waist circumference were 
significantly associated with incident vasomotor symptoms (VMS), occurring in early 
menopause, but a lower VMS risk in late menopause. However, no association was observed 
between changes in BMI or WC and incident VMS. Moreover, recent analysis from the Nurses’ 
Health Study II by Szegda et al19 showed that substantial weight loss may increase risk for early 
natural menopause. Women who lost ≥20 pounds from age 18 to 35 years had an increased odds 
of early menopause compared to women who gained 5 to 15 pounds. In addition, weight cycling 
between ages 18 to 30 was also associated with higher risk of early age at natural menopause. 
Ethnicity, in relation to adiposity and age at menopause, was not assessed due to the majority of 
the study population being White. 
 
To understand the postmenopausal health implications for both underweight and 
overweight women, further studies are needed to assess whether absolute weight and weight 
change play a role on menopausal age. Using a life course approach, determining the effect of 
changes in adiposity on the timing of menopause is important in order to understand the potential 
mechanisms by which these changes may act to affect age at menopause, which has been 
associated with increased risk for various health conditions. Most studies conducted on the effect 
of the change in adiposity on ANM have, on the whole, relied on recall of early adult weight, and 
not on objectively assessed measures such as, height, weight and WC. Using data from the 
CARDIA, this study examines the association between baseline, and longitudinal changes in 
premenopausal anthropometrics (weight, BMI and WC) and ANM. 
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2.2 Methods  
 Study Design, Sample and Data Collection 
The CARDIA study is a multicenter longitudinal study of 5,114 (including 2,786 women; 
one person revoked consent over the course of the study) adults aged 18 to 30 years, who were 
recruited at baseline (Year 0) in 1985-1986 from four US urban centers (Birmingham, Alabama; 
Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California) to examine cardiovascular 
risk factor trends in young adults. The response rate among individuals invited to participate was 
50%. This sample has been followed for the past 25 years, with follow-up examinations 
occurring during 1987–1988 (Year 2), 1990–1991 (Year 5), 1992–1993 (Year 7), 1995–1996 
(Year 10), 2000–2001 (Year 15), 2005–2006 (Year 20), and 2010–2011 (Year 25). A majority of 
the group has been examined at each of the follow-up examinations (91%, 86%, 81%, 79%, 
74%, 72%, and 72%, respectively). Approximately 88% of participants have attended ≥4 
CARDIA examinations. For the current investigation, data from all exam cycles (i.e., Years 0, 2, 
5, 7, 10, 15, 20, and 25) were included in the analyses. The sample was recruited to be balanced 
on sex, race (White or Black), age (18-24 or 25-30 years), and education (≤12, >12 years). Data 
collection and follow-up protocols were approved by the institutional review boards of each field 
center with all participants providing written informed consent. Details of the study design and 
methods are described elsewhere20. Women who did not attend the year 25 visit were more likely 
to be Black, younger, and current smokers, and to have fewer years of education at baseline20. At 
every CARDIA examination, standardized protocols were used to collect information on 
demographics, anthropometrics, lifestyle and behavioural factors, medical history, biomarkers, 
and medication use from participants. The study was approved by the institutional review boards 
from each field center and the coordinating center. Access to the CARDIA database with 
information from baseline to Year 25 was obtained from the National Heart, Lung and Blood 
Institute (NHLBI) for this analysis. Ethics approval was obtained for secondary data analysis for 
the present study from the York University Research Ethics Board. 
 
Sample Selection Criteria  
A woman’s anthropometric data from a particular exam were excluded if she was 
pregnant at that exam, although her other exam data were retained in the analyses. Women who 
had undergone menopause before 40 years of age (n=17) were excluded from this study, in order 
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to exclude women with premature ovarian insufficiency, which is of a different etiology than 
natural menopause. Women diagnosed with breast, ovarian, or endometrial cancers (n=19) were 
also excluded since treatment for these cancers includes hormone use which might mask the true 
age of menopause3. Also excluded were women who were missing data at follow up by Year 15, 
when menopause was first ascertained (n=558). Therefore, this analytic sample included 2192 
unique women with complete information on the outcome and exposures variables. Participants 
excluded from the analytic sample were more likely to be Black, and younger (by design) 20. 
Missing data on either weight, BMI or WC among women who completed the different cycles, 
ranged between 1-7%. Those with missing information on exposure variables at each cycle 
differed with respect to age, race, and education, and parity, presence of diabetes, hypertension, 
high cholesterol, and menopause status than those with complete information on those variables.   
 
Outcome variable 
Age at natural menopause is defined as the age of last menses, occurring after at least 12 
months of amenorrhea as per the WHO’s definition21. Age at natural menopause (ANM) was the 
outcome for this analysis. Menopausal status, captured at Year 15 (women were 33 to 45 years 
old), at year 20 (women were 38-50 years old), and at Year 25 (women were 43 to 55 years old) 
exams, was assessed with the question “Have you gone through menopause or the change of 
life?” followed by “If yes, how did your periods stop?” with the options of “naturally”, 
“surgically” or “other”.  Participants were then asked “How old were you when this occurred?” 
which was used in this analysis as age at menopause. Among postmenopausal women, those who 
reported cessation of menstrual bleeding not preceded by hysterectomy, radiation, or 
chemotherapy were classified as having a natural menopause, whereas those who reported 
menstrual cessation due to hysterectomy and/or bilateral oophorectomy were classified as having 
surgical menopause. Age at menopause was defined as self-reported age at natural cessation of 
menstrual flow or age at surgery to remove the uterus and/or ovaries. Women were additionally 
asked about ever use of oral contraceptives or current hormone therapy.  
 
Independent variables 
Anthropometric variables which comprise baseline weight, BMI, and WC, as well as 
changes in weight, BMI and WC, were the primary time-varying independent variables. 
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Anthropometrics were measured at each examination. Body mass index (BMI) was calculated by 
dividing weight in kilograms by height in meters squared. Body weight was measured on a 
calibrated balance scale while participants were dressed in light clothing and without shoes by 
trained and certified technicians using a calibrated scale. Height (without shoes) was assessed by 
using a vertical ruler and recorded to the nearest 0.5 cm. WC was measured at the minimum 
abdominal girth (to the nearest 0.5 cm). Due to its stronger correlation with visceral and 
abdominal obesity than waist to hip ratio (WHR) 18, WC was considered in the analysis rather 
than WHR. BMI categories include underweight (BMI<18.5 kg/m2), normal weight (BMI=18.5-
24.9 kg/m2), overweight (BMI=25-29.9 kg/m2) and obese (BMI≥30 kg/m2)22. Absolute changes 
in weight, BMI and WC were calculated by subtraction of the baseline measurement from each 
follow-up measurement. Absolute changes in weight, WC and BMI from the immediate prior 
visit were also obtained to assess for the role of recent changes in body size. Relative changes in 
BMI, weight and WC were quantified as the percent changes from baseline and the immediately 
prior visits. Changes in weight, WC and BMI were made categorical in order to make clinical 
recommendations easier to interpret, with the categories previously used by Gold et al 18. 
 
Covariates 
Time-varying covariates, measured at each exam, included sociodemographic factors, 
such as education (high school or less, more than high school), current employment (yes/no), and 
household income in USD (<25,000, 25,000-49,999, 50,000-99,999, ≥100,000); Health behavior 
variables that included smoking status (never, former, or current), alcohol consumption in the 
past year (yes/no), ever oral contraceptive (OC) use (yes/no), and self-reported physical activity 
intensity (vigorous/ moderate/ low). Cigarette smoking was assessed by means of an interviewer- 
administered tobacco questionnaire. Physical activity level was assessed using a modified 
version of the Minnesota Leisure Time Physical Activity Questionnaire, with total scores 
representing self-reported participation in 13 different categories of exercise over the past year, 
expressed in exercise units23. As a useful reference, 200 exercise units (EU) are roughly 
equivalent to regularly engaging in exercise at 6 METS (moderate intensity), such as stationary 
bicycling or swimming 2 h a week for 11 months per year. Vigorous physical activity intensity 
was defined as > 200 exercise units,  100- 200 exercise units corresponded to moderate intensity 
physical activity, while low intensity physical activity was defined as <100 exercise units. 
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Alcohol intake was defined as consumption of any alcoholic beverages in the past year. Clinical 
factors that included physical measurements (e.g. blood pressure), CVD markers, such as total 
cholesterol level, and parity (none versus 1 or more) were also considered as time varying 
covariates. At baseline, blood pressure was measured using a random-zero sphygmomanometer 
with participants seated and after 5 minutes of rest. At the 20-year follow-up examination, three 
measurements of seated blood pressure were taken from the right arm of each participant after 
resting for 5 minutes using an Omron HEM907XL automated BP monitor using an appropriately 
sized cuff and calibrated to the random-zero measures24. The average of the second and third 
consecutive measurements was used for analysis. Hypertension was defined as self-reported 
diagnosis of hypertension, or SBP>140mm Hg or DBP>90mm Hg or use of anti-hypertensive 
medications.  Before each CARDIA exam, participants fasted for ≥ 8 h and were asked to avoid 
smoking and heavy physical activity for the final 2 h. Blood was drawn by venipuncture 
according to a standard protocol20. Fasting glucose was measured using hexokinase coupled to 
glucose-6-phosphate dehydrogenase at a collaborative studies clinical laboratory (Minneapolis, 
MN) 25. Type 2 diabetes was defined as a self-reported diagnosis of diabetes, a fasting glucose 
level of at least 126 mg/dL (to convert to mmol/L, multiply by 0.0555), or reported use of 
diabetes medications. Blood samples were collected at each clinical center according to a 
common protocol. Fasting plasma total cholesterol, triglycerides (TG), and high-density 
lipoprotein cholesterol (HDL-C) were measured enzymatically by Northwest Lipid Research 
Laboratories (Seattle, Washington, D.C.)26. Low-density lipoprotein cholesterol (LDL-C) levels 
were calculated using the Friedewald equation26. Hyperlipidemia was defined as self-reported 
diagnosis of high cholesterol, a total cholesterol level of 240 mg/dL or greater (to convert to 
mmol/L, multiply by 0.0259), or use of high cholesterol medications. Details of quality control 
activities that were conducted at CARDIA field centers, coordinating centers, laboratories, and 
reading centers are available on the CARDIA website at www.cardia.dopm.uab.edu. For 
covariates with missing data (all<5%), missing values were assigned to a missing indicator 
category, and analyses using missing indicator categories were conducted to maximize statistical 
power. Results from analyses restricted to women with complete covariate data were 
comparable. For the purpose of this analysis, time invariant covariates, include race measured at 
baseline, parity measured at Year 5, and intake of protein, fat and carbohydrates (CHO). A 
quantitative food frequency (CARDIA Dietary History) was administered by a trained 
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interviewer at assess intake of protein, fats, and CHO, at baseline and Year 7. Intake of each food 
group was calculated as the sum of the number of times a food in each food group was eaten per 
day (g/d). The CARDIA dietary history is a reasonably reliable and valid (r=0.5-0.7; the 
CARDIA food questionnaire versus food diaries obtained from a subsample) dietary survey 
method for obtaining information about habitual intakes in both races22-25. The analyses were 
conducted using Year 7 dietary data, because the data were based on an updated and more 
extensive version of the food database22-25. The natural log of fasting insulin and dietary intake 
variables was taken since these variables were not normally distributed.   
 
Statistical Analysis 
   Baseline characteristics of the women were compared by menopausal status using chi-
square tests for categorical variables and Kruskal-Wallis tests for continuous variables. Due to 
the interrelationship between the main independent variables, namely weight, BMI and WC that 
constitute body size, baseline values and the change in these main independent variables were 
examined in separate models. Next, discrete–time survival analysis were used to determine the 
association between anthropometric measures at baseline, absolute and relative changes in  those 
measures and ANM while adjusting for the covariates listed above, including time-varying 
covariates. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for earlier or later 
ANM were then estimated by a series of separate Cox proportional hazards models. Women who 
did not experience menopause were considered as censored observations.  Age, rather than time 
until incident menopause, was used as the time scale for survival analysis in order to address left- 
truncation, the time at which participants contributed unobserved time at risk. The endpoint age 
was defined as one of the following: a) age at natural menopause for postmenopausal women 
(n=316), b) age at last follow up exam if a woman is premenopausal (n=1,372), c) age at 
hysterectomy or bilateral oophorectomy before having ≥12 consecutive months of untreated 
amenorrhea (n=324), and d) age at HT initiation (among women who had used HT prior to 
menopause) (n=18). Criteria for censored observations are similar to that used by Gold et al14.  
To assess for other potential confounders, non-intentional weight change due to non-
gynecological cancers or endocrine disrupting conditions, ulcerative colitis, Crohn’s disease, 
rheumatoid arthritis or systemic lupus throughout the study duration was determined. None of 
the women included in this analysis had developed these conditions. Women who underwent a 
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hysterectomy after menopause were not censored. Multivariate regression models included 
covariates selected a priori as factors associated with age at natural menopause and/or body size 
in the literature. Model 1 controlled for the following variables: education level, current 
employment, household income, OC use, smoking status, alcohol intake in the last year, physical 
activity intensity, and presence of type 2 diabetes, hypertension, and hyperlipidemia, dietary fat, 
CHO and protein intake, and parity, as well as fasting glucose, insulin, total cholesterol, LDL-C, 
HDL-C, TG, Systolic and Diastolic BP. Model 2 was identical to model 1 but excluded type 2 
diabetes, hypertension and hyperlipidemia. The reason for creating two distinct models was to 
address collinearity between metabolic and chronic conditions variables, especially when 
variance inflation factor (VIF) values were more than 2.5 for some metabolic markers. The 
assumption of proportional hazards was checked both by inspection plots and Schoenfeld 
residuals, which did not indicate violation of the assumption (Appendix A). Goodness of fit of 
the multivariate Cox models was assessed using the likelihood ratio test and Cox-Snell residuals, 
which indicated a good overall fit (Appendix A). Statistical analysis was performed using 
STATA software, version 13.0. Statistical significance was set at α = 0.05. To minimize multiple 
comparison bias, a post hoc Bonferroni correction was applied, with the uncorrected confidence 
intervals presented here being similar to those with correction. 
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2.3 Results  
 
Table 1 shows the baseline characteristics by the menstrual status. The majority of 
women were still premenopausal (67.3%), while 16.5% were naturally menopausal. The median 
ANM among women in the CARDIA was 52 years (Interquartile range: 50-54). Blacks were 
more likely to be pre-menopausal, or were more likely to use HT before menopause than Whites. 
Higher education level was associated with being premenopausal. Women who had a higher 
household income (50,000-99,999 USD), who were employed, who were current smokers, were 
more likely to be premenopausal or to be using HT before menopause. Women who were 
diagnosed with diabetes, hypertension or hyperlipidemia, were more likely to be pre-
menopausal. The majority of women had gained >10% in weight (29.8%), BMI (28.9%) and WC 
(27%) since baseline, as Table 2 shows. Women were more likely to have gained 1-5% in weight 
(13.6%), BMI (12.9%), and WC (14.9%), respectively, from one visit to the next.  
 
Results of the adjusted Cox regression models with weight, BMI and WC as time-varying 
variables are outlined in Tables 3a, 3b and 3c. Earlier ANM was strongly associated with current 
smoking in both models. The following variables were also significantly related to an earlier 
ANM in both models and across anthropometric measures: past smoking, fat intake change and 
changes in diastolic and systolic blood pressure. Pre-menopausal hypertension was strongly 
associated with an earlier ANM in the model for weight (HR=1.32; 95% CI=1.04-1.66), BMI 
(HR=1.32; 95% CI=1.05-1.68), and WC (HR=1.35; 95% CI=1.05-1.68), respectively. Baseline 
WC (HR=0.98; 95% CI=0.97-0.99) was significantly related to a later ANM in models 1 and 2. 
A higher education level was also associated with later ANM in all anthropometric measures. 
Baseline weight, BMI, and changes in anthropometric measures were not associated with ANM.  
 
Multivariate Cox regression of the study participants’ changes in anthropometrics as a 
categorical variable, showed that if there was >5% weight loss since baseline, the hazard rate for 
an earlier ANM decreased by 45% (HR=0.55, 95% CI=0.31-0.97). This association was no 
longer statistically significant when hypertension, diabetes and hyperlipidemia were removed 
from the analysis, as shown in Table 4.  
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2.4 Discussion 
 
The aim of this study was to assess whether baseline and longitudinal changes in 
adiposity are associated with ANM. No association between changes in anthropometrics across 
time and onset of menopause was observed; but, baseline WC was negatively associated with 
ANM. Moreover, the presence of hypertension prior to menopause was also associated with an 
earlier ANM. It was found that women who lost more than 5% of their weight since baseline 
measurement did have a later menopause than women with stable weight, after controlling for  
potential confounding variables. Findings might inform prevention strategies that benefit many 
women going through the menopausal transition, highlighting the importance of both control and 
prevention of cardiovascular risk factors, especially blood pressure, in adulthood prior to 
menopause when cardiovascular risk factors are prone to change. 
 
The lack of association found between any changes in anthropometrics throughout the 
study period was similar to Hardy et al13, who using a nationally representative British cohort of 
1583 women born in March 1946 reported no relationship between a BMI trajectory from 20 to 
36 years and ANM. Similarly, Gold et al18, using data from the SWAN, showed that percentage 
weight change since baseline and since prior visit were unrelated to any incident vasomotor 
symptoms (VMS), a proxy to menopause onset, in either early or late menopause. This is also in 
concordance with Galicchio et al34 who in a longitudinal study of midlife women demonstrated 
that change in BMI and weight over 1‐5 years of follow up was not linked to hot flashes in two 
racial groups. In contrast, women who reported severe weight cycling i.e. women who lost ≥20 
pounds three or more times between ages 18 and 35, had higher odds (OR=1.48, 95%CI=1.04, 
2.10) of early natural menopause compared to normal weight women, as data from the Nurses’ 
Health Study 2 (NHS2), revealed19. Weight change in that study was calculated by subtracting 
weight at age 18 from that at age 35. The study’s assessment of longitudinal changes of adiposity 
measures was limited to premenopausal women until age 35 with weight loss or gain being self –
reported.  Morris et al16 observed that a greater weight gain from 20 to 40 years of age was 
associated with a later menopause (HR=0.93, 95%CI=0.87, 0.98) after adjustment for BMI at 
age 40 years and other factors.  
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Although several studies indicate that overweight decelerates menopause, others note no 
effect of body weight menopause onset3, 4, 13, 14, 27, 28. Of those that found an association, large 
weight gain from age 20 years3 was related to a later menopause and large weight losses to an 
earlier menopause12. Our conflicting result that women with weight loss of more than 5% since 
baseline had a later menopause might be due to residual confounding by age or other factors such 
as endogenous hormone levels15 (e.g. follicular stimulating hormone and estradiol). Our result 
was similar to that of Aydin 15 who, in a cross-sectional study, conducted among postmenopausal 
Turkish women, found that weight loss of more than 5 kg was involved in postponing 
menopause. In fact, women with low BMI have high levels of Anti-Mullerian Hormone (AMH) 
19, a marker of ovarian reserve related to antral follicle count that is produced by the granulosa 
cells in the ovary, indicating a low risk for earlier menopause. Over a quarter of women in our 
sample who had lost more than 5% of their weight were overweight at baseline (data not shown), 
and so they may be more likely to intentionally lose weight throughout the years. Although we 
were able to adjust for several potential confounding factors, confounding by unknown or 
unmeasured covariates, such as hormone levels and changes in dietary habits and physical 
activity, cannot be ruled out. Therefore, this result might be spurious. Aging also results in a 
decrease in lean body mass, which decreases resting metabolic rate31. Although estrogen 
deprivation after menopause leads to an increase in total body fat, it also results in a decrease in 
lean body mass, such that there is little net effect on weight related to menopause alone32. It 
might be that women who lost more than 5% of their weight over 25 years of follow up have lost 
muscle more than fat. Additional studies should assess longitudinal relationships between birth 
weight, early life adiposity, and ANM.  
 
Consistent with previous research, another finding from our analysis was that 
premenopausal hypertension was strongly associated with an earlier menopause among women 
in the CARDIA. Analysis from the Korea National Health and Nutrition Examination Survey 
(KNHANES)36, based on 13,584 women, also noted that hypertension diagnosed before age 40  
was associated with an earlier ANM (HR=1.03, 95% CI=1.02-1.03). In fact, middle-aged women 
require careful monitoring during the menopausal transition. For example, a study also using the 
CARDIA by Ebong et al38 documented an association between high sensitivity C - reactive 
protein (hs-CRP), an inflammatory biomarker, and hypertension among premenopausal women, 
 19  
independent of BMI. Estrogen is thought to protect against CVD in premenopausal women via 
both systemic and local vascular effects. These vasoprotective effects are mediated in part 
through the binding of estrogen to vascular endothelial cells and smooth muscle cells, affecting 
their function and resulting in decreased vasoconstriction and blood pressure39, 40. Weight, 
cholesterol level, diabetes mellitus, blood pressure, and smoking have negative vascular effects, 
but may also affect hormone production, which in turn could have an impact on menopausal age 
by altering estrogen levels. Therefore, the interplay and overlap between the effects of 
inflammation, obesity and estrogen loss may contribute to the development of hypertension in 
the postmenopausal period. Our results showed that systolic blood pressure and diastolic blood 
pressure were both associated with age at menopause, which is in concordance with results from 
the Framingham Heart study17. Data from Janssen et al41 also found that progression through 
menopause was associated with an increase in the incidence of the metabolic syndrome (MetS) 
where the odds of developing MetS were 1.45 (95% CI=1.35-1.56) per year during the 
perimenopause and 1.24 (95% CI=1.18-1.30) per year in the postmenopausal years.  
 
Our results showed that any change in dietary fat intake per day was associated with an 
earlier ANM. The few prospective cohort and cross-sectional studies that have investigated the 
effect of dietary fat on menopause timing have had inconsistent results7, 42-46. A German cohort 
study reported that higher total intakes of fat, meat and protein were all correlated with later 
onset of menopause44. On the contrary, another study using NHS2 data45 found that only a daily 
intake vegetable-based protein was associated with a later ANM.  Further longitudinal research is 
needed to elucidate the relation of dietary factors with ANM. In addition, factors consistently 
related with age at menopause such as higher education levels, and current smoking status were 
significantly associated with ANM as indicated in other studies3-7, 14. 
 
Baseline WC was a consistent, yet modest predictor of later ANM in both models, as per 
the results of the multivariate Cox regression. A possible explanation for this result might lie in 
the fact that WC is a better predictor of and correlated with cardiovascular risk factors such as 
hypertension, dyslipidemia, and MetS than BMI and weight 47. Vice versa, SBP, DBP, 
cholesterol levels, glucose levels, and diabetes are also independent predictors of WC 47, 48. 
Moreover, a post hoc regression analysis of our data also revealed that hypertension, diabetes 
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and insulin levels were prominent predictors of WC. Baseline body size measures are highly 
correlated with current body size35, 36, therefore our result might be in line with the notion that 
premenopausal obesity delays menopause. Our results were similar to Gold et al18 who noted that 
higher WC was significantly associated with lower VMS risk in late menopause. It should be 
noted that while body size indicators often increase with age, the current analysis could not 
distinguish between period effects and life transitions.  
 
Strengths and Limitations 
The strengths of the present study include the detailed exposure and outcome information 
available. This is the first study to evaluate associations of three dynamic body size indicators as 
risk factors of ANM. CARDIA’s design provides a clear temporality between exposure and 
outcome, and thus builds upon previous literature. Furthermore, the adjustment of multiple 
established risk factors and censoring at age of initiation of hormone therapy and age at surgical 
menopause limits the potential for confounding bias. All anthropometrics were objectively 
assessed and obtained across all cycles, therefore allowing examination of body size prior to 
menopause and avoiding the potential for recall or reporting bias observed in previous studies. 
Indeed, few previous studies have considered BMI or weight in earlier adult life or change in 
these measures, and most of those that have were limited by recall bias resulting from the use of 
retrospective self-reported measures of earlier weight3, 12,13,16,19. The bi-racial nature of the cohort 
also enabled examining associations across racial groups. Moreover, many of the potential 
confounding variables were considered to be time-variant so their associations with ANM can be 
taken as meaningful.   
Nonetheless, a few caveats should be mentioned. First, generalizability might be limited 
due to the self-selected nature of the sample. Recall bias due to self-report of ANM might be 
another limitation; however, reporting of menopause has been found to be highly reproducible14, 
50. The data were subject to right censoring because participants had “survived” (not yet 
postmenopausal). A large proportion of women in the youngest age groups had not yet reached 
menopause, but the analysis methods, which are standard for this type of study4, 14, allowed for 
their inclusion. Our data were also left-truncated since women with a reported age at menopause 
below age 40 were not present in the sample. However, our analyses accounted for entry at ages 
40 years and above. Lastly, some of our results might be due to chance given the number of 
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multiple comparisons; however, this has been minimized after performing a post hoc Bonferroni 
correction and comparing the corrected and uncorrected confidence intervals, which were 
similar. 
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2.5 Conclusion 
 
This study is one of the few prospective studies of objectively assessed anthropometric 
measures and ANM.  Taken together, these findings suggest that baseline WC, and more than a 5 
% loss of baseline weight are modest predictors of ANM in middle-aged women. Modest effect 
sizes for the relationship between longitudinal changes in body size indicators and ANM were 
obtained, yet they are of clinical significance since results were consistent with previous 
research. Premenopausal hypertension and blood pressure indicators were also significantly 
related to an earlier ANM, highlighting that menopausal age is at least in part determined by 
modifiable factors. Further research is warranted on the role of longitudinal changes in adiposity 
and ANM. A better understanding of how weight gain or loss affects menopause onset and 
ovarian aging may help inform women and their health care providers of ways to modify their 
risk of an earlier menopause and the health conditions associated with it.  
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Figure 2.1: Flowchart of participants in the CARDIA study 
 
 
2,192 women eligible for analysis 
2,786 women enrolled at Year 0 (1985-1986) 
Excluded: 
19 women diagnosed with female cancers (breast or 
uterine or cervical) 
17 women with ANM<40 years 
558 women missing follow up before year 15  
(When menopause first captured) 
316 women reached natural menopause by Year 25 (2010-2011) 
Censoring events: 
 1,372 pre-menopause 
 324  surgical menopause 
 18  initiated HT before menopause 
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    Table 2.1: Baseline sociodemographic, health behaviour, and clinical characteristics of women in the study sample by menstrual status, CARDIA (1985-2011). 
 Total Pre-menopause 
(n=1,372) 
Natural 
Menopause 
(n=316) 
Surgical 
Menopause 
(n=324) 
HT use prior to  natural 
menopause 
(n=18) 
Characteristics      
Age , years, (mean, SD) 24.8(3.65) 24.0(3.59) 27.9(2.28) 26.25(3.12) 28.5(1.92) 
Race (n, %)      
White 1,204 (47.0) 709(70.7) 205(20.4) 89(8.9) 3(6.82) 
Black 1,357(53.0) 663(65.7) 111(11.0) 235(23.3) 14(25.5) 
Educational level (n, %)      
High school graduate or less 966(35.2) 480(67.6) 84(11.8) 146(20.6) 3(10.3) 
More than High school 1,780(64.8) 892(68.5) 232(17.8) 178(13.7) 14(20.0) 
Income, USD* (n, %)      
<25,000 748(38.9) 427(67.7) 95(15.1) 109(17.3) 4(16.0) 
25,000-49,999 704(36.7) 430(71.3) 81(13.4) 92(15.3) 4(14.3) 
50,000-99,999 273(14.2) 161(66.3) 52(21.4) 30(12.4) 7(30.4) 
≥ 100,000 -- -- -- -- -- 
Currently Employed (n, %) 1,666(65.1) 888(66.5) 236(17.7) 212(15.9) 16(20.5) 
Smoking  Status      
Never 1,468(57.5) 846(71.0) 161(13.5) 184(15.5) 8(15.1) 
Past 349(13.7) 196(67.4) 55(18.9) 40(13.8) 4(25.0) 
Current 736(28.8) 327(62.5) 97(18.6) 99(18.9) 4(13.8) 
Alcohol intake in the last year (n, %) 2,145(83.6) 1,161(68.5) 277(16.3) 257(15.2) 16(18.4) 
Oral contraceptive use (n, %) 814(41.7) 473 (74.5) 75(11.8) 87(13.7) 5(18.5) 
Physical activity intensity, exercise units, (mean, SD) 335(249.7) 354(260) 362(240) 284(241) 459.3(296) 
Parity (n, %)      
1 or more 2,577(93.9) 1,272(68.4) 292(15.7) 296(15.9) 16(17.0) 
Weight, Kg, (mean, SD) 72.5(19.0) 72.1(19.4) 70.8(17.2) 75.8(18.7) 69.3(13.6) 
Waist circumference (WC), cm, (mean, SD) 74.0(11.0) 73.70(11.00) 73.2(10.2) 76.1(10.9) 70.2(7.30) 
BMI, Kg/m2 (mean, SD) 24.5(5.52) 24.3(5.38) 23.9(5.15) 25.5(5.64) 22.9(3.64) 
Dietary fat, g/day, (mean, SD)a 98.9(71.5) 95.93(70.8) 94.5(61.4) 102(56.9) 67.7(21.4) 
Dietary CHO, g/day, (mean, SD)a 216(131.6) 214(129.5) 205(115.6) 217(119.6) 166.9(70.8) 
Dietary protein, g/day, (mean, SD)a 76.6(53.6) 75.0(50.12) 77.4(55.8) 74.5(38.2) 62.8(19.0) 
Fasting glucose, mg/dl, (mean, SD) 80.8(16.8) 80.2(13.24) 81.5(15.7) 81.5(15.3) 79(12.3) 
Fasting insulin, mg/dl, (mean, SD) 11.4(8.34) 11.16(8.10) 9.4(6.03) 12.5(9.7) 7.6(2.80) 
HDL cholesterol, mmol/L,(mean, SD) 55.3(12.8) 55.0(12.8) 58.4(12.7) 54.8(12.6) 66.3(8.40) 
LDL cholesterol, mmol/L,(mean, SD) 108(30.2) 109(30.2) 105(31.4) 110(29.3) 99.5(27.5) 
Triglycerides, mmol/L, (mean, SD) 66.1(35.0) 66.9(36.9) 62.0(30.1) 68.7(34.2) 53.3(22.2) 
Total cholesterol, mmol/L, (mean, SD) 177(32.7) 178(32.5) 175(32.0) 179(30.5) 170.3(26.3) 
Systolic blood pressure, mm Hg , (mean, SD) 106(9.62) 106(9.22) 104(9.12) 107(9.67) 100.8(8.52) 
Diastolic blood pressure, mm Hg , (mean, SD) 66.7(8.90) 67.0(8.53) 65.2(8.60) 67.6(8.80) 62.7(9.00) 
Current Diabetes (n, %) 261(9.50) 29(51.8) 6(10.7) 21(37.5) 0 
Current Hypertension (n, %) 403(14.7) 108(65.5) 19(11.5) 38(23.0) 0 
Current Hyperlipidemia (n, %) 355(12.9) 83(65.4) 23(18.1) 21(16.5) 0 
a Information not available at year 0; year at which characteristic was first assessed was taken as baseline. 
*Chi-square test for categorical variables; Kruskal-Wallis test for continuous variables; majority had p-values of <0.001. 
Note: percentages in the last four columns are row %, however only the %’s within the first three of those columns add to a 100%, since HT use prior to menopause was a variable on its own (yes/no). 
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Table 2.2:  Total percent distribution of relative longitudinal changes in anthropometric measures among 
women in the CARDIA, (1985-2011). 
 Weight BMI WC 
Relative change  since baseline, per 1%   % % % 
 Lost >5% 4.25 4.61 3.30 
 Lost 1%-5% 4.73 5.06 5.42 
 Stable 14.9 14.7 14.9 
 Gained 1%-5% 8.31 8.37 9.77 
 Gained>5%-10% 9.89 9.92 11.1 
 Gained>10% 29.8 28.9 27.0 
Relative change since prior visit, per 1%     
 Lost >5% 6.01 6.19 5.12 
 Lost 1%-5% 7.60 8.00 8.68 
 Stable 6.43 6.32 6.59 
 Gained 1%-5% 13.6 12.9 14.9 
 Gained>5%-10% 11.5 11.4 11.4 
 Gained>10% 9.33 9.44 7.33 
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Table 2.3a: Adjusted Hazard Ratios (HRs) for the association between weight and ANM in the CARDIA, 
(1985-2011). 
 Model 1* Model 2¥ 
 HR 95%CI HR 95%CI 
Baseline Weight 0.99 0.99-1.02 0.99 0.99-1.01 
Time-varying Weight 1.00 0.99-1.00 1.00 0.99-1.01 
Race      
Black 0.92 0.74-1.15 0.92 0.74-1.15 
Educational level      
High school graduate or less 1.00     1.00  
More than High school 0.77 0.62-0.97a 0.75   0.60-0.94 a 
Household income, USD     
<25,000 1.00     1.00  
25,000-49,999 1.09 0.83-1.44 1.06 0.84-1.32 
50,000-99,999 0.95 0.70-1.31 0.92  0.71-1.21 
≥100,000 1.09 0.72-1.65 1.07  0.73-1.56 
Currently Employed  0.95 0.80-1.13 0.95  0.80-1.13 
Smoking  Status     
Never 1.00  1.00  
Past 1.24 1.03-1.50a 1.25 1.03-1.51a 
Current 1.87 1.46-2.40b 1.86 1.45-2.40b 
Alcohol intake in the last year  1.11 0.86-1.41 1.12  0.87-1.42 
Oral Contraceptive use 0.82 0.66-1.03 0.91 0.75-1.11 
Physical Activity      
 Low Intensity 1.00  1.00  
 Moderate Intensity 0.98 0.75-1.29 0.95 0.72-1.25 
 High Intensity 1.09 0.86-1.38 1.11 0.87-1.40 
Parity      
1 or more 1.17 0.88-1.56 1.17 0.88-1.56 
Diabetes  0.74 0.47-1.16 -- -- 
Hypertension  1.32 1.04-1.66a -- -- 
Hyperlipidemia  0.96 0.74-1.22 -- -- 
Log Dietary fat, g/day 1.37 1.01-1.84a 1.35 1.00-1.81 
Log Dietary CHO, g/day 0.83 0.61-1.12 0.83 0.61-1.12 
Log Dietary protein, g/day 1.01 0.69-1.49 1.02 0.69-1.50 
Fasting glucose, mg/dl,  0.99 0.99-1.01 0.99 0.99-1.01 
Log Fasting insulin, mg/dl,  1.01 0.99-1.02 0.94 0.76-1.15 
HDL cholesterol, mmol/L 1.05 0.86-1.29 1.06 0.87-1.30 
LDL cholesterol, mmol/L 1.05 0.85-1.28 1.05 0.86-1.29 
Triglycerides, mmol/L,  1.01 0.97-1.05 1.01 0.97-1.05 
Total cholesterol, mmol/L,  0.96 0.78-1.17 0.95 0.78-1.17 
Systolic blood pressure, mm Hg  0.98 0.97-0.99b 0.98 0.98-0.99b 
Diastolic blood pressure, mm Hg  1.02 1.01-1.03b 1.02 1.01-1.04b 
*Model 1: Adjusted for the following covariates in addition to baseline values for  weight: Time-varying covariates include education, current employment, 
household income, OC use, current smoking, alcohol intake in the last year, physical activity intensity, and presence of diabetes, hypertension and 
hyperlipidemia, in addition to Fasting glucose, insulin, LDL-C, HDL-C, TG, Total cholesterol, Systolic and Diastolic BP. Time invariant covariates include 
race, dietary fat, CHO and protein intake and parity. 
 
¥ 
Model 2 was adjusted to include all variables in model 1 except: diabetes, hypertension and hyperlipidemia. 
                   a p- value≤0.05; b p-value≤0.0001 
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   Table 2.3b: Adjusted Hazard Ratios (HRs) for the association between BMI and ANM in the CARDIA, 
(1985-2011). 
 Model 1* Model 2¥ 
 HR 95%CI HR 95%CI 
Baseline BMI, kg/m2 0.98 0.95-1.01 0.97 0.94-1.00 
Time-varying BMI 0.99 0.98-1.02 1.01 0.98-1.03 
Race      
Black 0.94 0.75-1.17 0.94 0.75-1.17 
Educational level      
High school graduate or less 1.00  1.00  
More than High school 0.77 0.62-0.96a 0.75 0.60-0.94a 
Household income, USD     
<25,000 1.00  1.00  
25,000-49,999 1.08 0.82-1.43 1.05 0.84-1.31 
50,000-99,999 0.94 0.68-1.29 0.91 0.70-1.19 
≥100,000 1.08 0.71-1.63 1.06 0.72-1.54 
Currently Employed  0.96 0.81-1.15 0.96 0.81-1.15 
Smoking  Status     
Never 1.00  1.00  
Past 1.25 1.03-1.52a 1.26 1.04-1.52a 
Current 1.89 1.47-2.41b 1.88 1.47-2.42b 
Alcohol intake in the last year  1.10 0.86-1.40 1.11 0.87-1.41 
Oral Contraceptive use 0.82 0.65-1.03 0.91 0.75-1.12 
Physical Activity      
 Low Intensity 1.00  1.00  
 Moderate Intensity 0.99 0.75-1.31 0.96 0.73-1.26 
 High Intensity 1.08 0.86-1.40 1.10 0.87-1.39 
Parity      
1 or more 1.16 0.87-1.55 1.16 0.87-1.55 
Diabetes  0.75 0.48-1.19 -- -- 
Hypertension  1.32 1.05-1.68a -- -- 
Hyperlipidemia  0.95 0.74-1.21 -- -- 
Log Dietary fat, g/day 1.36 1.01-1.84a 1.35 1.00-1.81 
Log Dietary CHO, g/day 0.83 0.61-1.12 0.83 0.61-1.12 
Log Dietary protein, g/day 1.02 0.70-1.50 1.03 0.70-1.51 
Fasting glucose, mg/dl,  1.01 0.99- 1.01 0.99 0.99-1.01 
Log Fasting insulin, mg/dl,  1.01 0.99- 1.02 0.96 0.78-1.18 
HDL cholesterol, mmol/L 1.06 0.86- 1.30 1.07 0.87-1.30 
LDL cholesterol, mmol/L 1.05 0.86- 1.29 1.06 0.86-1.29 
Triglycerides, mmol/L,  1.01 0.97- 1.05 1.01 0.97-1.05 
Total cholesterol, mmol/L,  0.95 0.78- 1.16 0.95 0.77-1.16 
Systolic blood pressure, mm Hg  0.98 0.98-0.99a 0.98 0.98-0.99a 
Diastolic blood pressure, mm Hg  1.02 1.01-1.03a 1.02 1.01-1.04a 
*Model 1: Adjusted for the following covariates in addition to baseline values for BMI: Time-varying covariates include education, current employment, 
household income, OC use,  current smoking, alcohol intake in the last year, physical activity intensity, and presence of diabetes, hypertension and 
hyperlipidemia, in addition to Fasting glucose, insulin, LDL-C, HDL-C, TG, Total cholesterol, Systolic and Diastolic BP. Time invariant covariates include race, 
dietary fat, CHO and protein intake and parity. 
 
¥ 
Model 2 was adjusted to include all variables in model 1 except: diabetes, hypertension and hyperlipidemia. 
a p- value<0.05; b p-value<0.0001
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Table 2.3c: Adjusted Hazard Ratios (HRs) for the association between waist circumference and ANM in 
the CARDIA, (1985-2011). 
 Model 1* Model 2¥ 
 HR 95%CI HR 95%CI 
Baseline WC, cm 0.98 0.97-0.99a 0.98 0.97-0.99a 
Time-varying WC 1.01 0.99-1.02 1.01 0.99-1.02 
Race      
Black 0.91 0.72-1.13 0.91 0.73-1.13 
Educational level      
High school graduate or less 1.00  1.00  
More than High school 0.77 0.61-0.95a 0.74 0.59 -0.92a 
Household income, USD     
<25,000 1.00  1.00  
25,000-49,999 1.06 0.80-1.40 1.04 0.83-1.30 
50,000-99,999 0.91 0.66-1.25 0.89 0.68-1.16 
≥100,000 1.08 0.71-1.62 1.06 0.73-1.55 
Currently Employed  0.95 0.80-1.13 0.95 0.79-1.13 
Smoking  Status     
Never 1.00  1.00  
Past 1.23 1.02-1.50a 1.24 1.02-1.50a 
Current 1.89 1.47-2.41b 1.87 1.46-2.40b 
Alcohol intake in the last year  1.12 0.88-1.44 1.14 0.89-1.45 
Oral Contraceptive use 0.81 0.65-1.02 0.89 0.74-1.10 
Physical Activity      
 Low Intensity 1.00  1.00  
 Moderate Intensity 0.97 0.74 -1.28 0.93 0.71-1.23 
 High Intensity 1.09 0.87-1.30 1.11 0.84-1.40 
Parity      
1 or more 1.17 0.88-1.56 1.17 0.88-1.56 
Diabetes  0.76 0.48-1.19 -- -- 
Hypertension  1.35 1.05-1.68a -- -- 
Hyperlipidemia  0.96 0.75-1.23 -- -- 
Log Dietary fat, g/day 1.38 1.03-1.86a 1.36 1.01-1.84a 
Log Dietary CHO, g/day 0.81 0.60-1.10 0.82 0.60-1.11 
Log Dietary protein, g/day 1.01 0.99-1.01 1.01 0.69-1.49 
Fasting glucose, mg/dl,  0.99 0.99-1.01 0.99 0.99-1.01 
Log Fasting insulin, mg/dl,  1.01 0.99- 1.02 0.93 0.76-1.15 
HDL cholesterol, mmol/L 1.04 0.85- 1.28 1.04 0.85-1.28 
LDL cholesterol, mmol/L 1.04 0.85- 1.27 1.04 0.85-1.27 
Triglycerides, mmol/L,  1.01 0.97- 1.05 1.01 0.97-1.05 
Total cholesterol, mmol/L,  0.97 0.79- 1.18 0.97 0.79-1.18 
Systolic blood pressure, mmHg  0.98 0.98- 0.99a 0.98 0.97-0.99a 
Diastolic blood pressure, mmHg  1.02 1.01-1.03a 1.02 1.01-1.04a 
*Model 1: Adjusted for the following covariates in addition to baseline values for WC: Time-varying covariates include education, current employment, household 
income, OC use,  current smoking, alcohol intake in the last year, physical activity intensity, and presence of diabetes, hypertension and hyperlipidemia, in addition to 
Fasting glucose, insulin, LDL-C, HDL-C, TG, Total cholesterol, Systolic and Diastolic BP. Time invariant covariates include race, dietary fat, CHO and protein intake 
and parity.  
¥ 
Model 2 was adjusted to include all variables in model 1 except: diabetes, hypertension and hyperlipidemia. 
a p- value<0.05; b p-value<0.0001 
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                 Table 2.4: Hazard Ratios (HR) for the Association between longitudinal changes in anthropometric measures and ANM in the CARDIA, (1985-2011) 
 Unadjusted   Model 1* Model 2¥ 
Relative change in weight since baseline, per 1%  HR 95%CI HR 95%CI HR 95%CI 
 Lost >5% 0.79 0.65-0.97* 0.55 0.31-0.97 a 0.51 0.26-1.00 
 Lost 1%-5% 1.01 0.84-1.20 0.92 0.55-1.54 1.04 0.57-1.91 
 Stable 1.00  1.00  1.00  
 Gained 1%-5% 0.98 0.84-1.14 0.72 0.45-1.15 0.65 0.36-1.15 
 Gained>5%-10% 0.92 0.80-1.06 0.72 0.46-1.12 0.67 0.39-1.15 
 Gained>10% 0.99 0.88-1.11 0.72 0.48-1.08 0.67 0.40-1.11 
Relative change in weight since prior visit, per 1%        
 Lost >5% 1.01 0.83-1.23 1.29 0.90-1.82 1.14 0.74-1.76 
 Lost 1%-5% 1.01 0.84-1.21 1.05 0.76-1.46 0.90 0.61-1.31 
 Stable 1.00  1.00  1.00  
 Gained 1%-5% 1.05 0.89-1.23 1.15 0.85-1.55 1.11 0.78-1.57 
 Gained>5%-10% 0.90 0.75-1.07 0.99 0.71-1.38 0.72 0.48-1.09 
 Gained>10% 1.07 0.89-1.28 1.01 0.71-1.43 0.86 0.56-1.31 
Relative change in BMI  since baseline, per 1%       
 Lost >5% 0.81 0.66-0.99* 0.86 0.48-1.52 0.78 0.39-1.57 
 Lost 1%-5% 1.01 0.84-1.19 1.26 0.73-2.16 1.41 0.75-2.64 
 Stable 1.00  1.00  1.00  
 Gained 1%-5% 1.03 0.88-1.19 0.95 0.57-1.57 0.92 0.50-1.67 
 Gained>5%-10% 0.95 0.82-1.10 1.02 0.63-1.66 1.08 0.61-1.91 
 Gained>10% 1.03 0.92-1.16 0.96 0.61-1.51 0.96 0.56-1.64 
Relative change in BMI since prior visit, per 1%       
 Lost >5% 1.08 0.88-1.32 1.11 0.71-1.71 1.13 0.73-1.75 
 Lost 1%-5% 1.07 0.89-1.29 1.06 0.72-1.56 1.05 0.71-1.55 
 Stable 1.00  1.00  1.00  
 Gained 1%-5% 1.08 0.91-1.27 1.15 0.80-1.65 1.18 0.82-1.68 
 Gained>5%-10% 0.95 0.79-1.13 0.89 0.60-1.31 0.91  0.61-1.34 
 Gained>10% 1.16 0.96-1.39 0.91 0.60-1.40 0.93  0.61-1.43 
Relative change in WC since baseline, per 1%       
 Lost >5% 0.95 0.75-1.20 0.49 0.22-1.08 0.46 0.21-1.02 
 Lost 1%-5% 1.02 0.85-1.22 0.70 0.38-1.26 0.69 0.38-1.26 
 Stable 1.00  1.00  1.00  
 Gained 1%-5% 1.14 0.99-1.31 0.67 0.41-1.09 0.64 0.39-1.03 
 Gained>5%-10% 1.01 0.87-1.16 0.69 0.43-1.11 0.68 0.42-1.08 
 Gained>10% 1.11 0.98-1.25 0.74 0.48-1.14 0.74 0.48-1.14 
Relative change in WC since prior visit, per 1%       
 Lost >5% 1.04 0.84-1.28 0.85 0.55-1.33 0.85 0.54-1.32 
 Lost 1%-5% 1.01 0.84-1.21 1.02 0.68-1.52 0.99 0.67- 1.48 
 Stable 1.00  1.00  1.00  
 Gained 1%-5% 1.12 0.95-1.32 0.87 0.61-1.24 0.87 0.61-1.24 
 Gained>5%-10% 1.06 0.89-1.26 0.85 0.57-1.25 0.85 0.57-1.25 
 Gained>10% 1.14 0.94-1.38 0.86 0.55-1.33 0.86 0.56-1.34 
*Model 1: Adjusted for the following covariates in addition to baseline values for each adiposity measure: Time-varying covariates include education, current employment, household income, OC use, current smoking, 
alcohol intake in the last year, physical activity intensity, and presence of diabetes, hypertension and hyperlipidemia, in addition to Fasting glucose, insulin, LDL-C, HDL-C, TG, Total cholesterol, Systolic and Diastolic 
BP. Time invariant covariates include race, dietary fat, CHO and protein intake and parity.  
¥ Model 2 was adjusted to include all variables in model 1 except: diabetes, hypertension and hyperlipidemia. 
a p- value≤0.05
 30  
 
References: 
1. Paramsothy P, Harlow SD, Elliott MR, Yosef M, Lisabeth LD, Greendale GA, Gold EB, 
Crawford SL, Randolph Jr JF. Influence of race/ethnicity, body mass index, and 
proximity of menopause on menstrual cycle patterns in the menopausal transition: the 
Study of Women’s Health across the Nation. Menopause. 2015; 1; 22(2):159-65. 
2. Rowland AS, Baird DD, Long S, Wegienka G, Harlow SD, Alavanja M, Sandler DP. 
Influence of medical conditions and lifestyle factors on the menstrual cycle. Epidemiol. 
2002; 1;13(6):668-74. 
3. Bromberger, J.T., Matthews, K.A., Kuller, L.H., Wing, R.R., Meilahn, E.N. and 
Plantinga, P. Prospective study of the determinants of age at menopause. Am J 
Epidemiol, 1997; 145(2), 124-133. 
4. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural 
menopause in a multiethnic sample of midlife women. Am J Epidemiol. 2001; 
153(9):865–874. 
5. Henderson KD, Bernstein L, Henderson B, et al. Predictors of the timing of natural 
menopause in the Multiethnic Cohort Study. Am J Epidemiol. 2008; 167(11):1287–1294. 
6. de Vries E, den Tonkelaar I, van Noord PA, et al. Oral contraceptive use in relation to 
age at menopause in the DOM cohort. Hum Reprod. 2001;16(8):1657–1662. 
7. Dorjgochoo T, Kallianpur A, Gao YT, et al. Dietary and lifestyle predictors of age at 
natural menopause and reproductive span in the Shanghai Women’s Health Study. 
Menopause. 2008; 15(5):924–933. 
8. Tao X, Jiang A, Yin L, Li Y, Tao F, Hu H. Body mass index and age at natural 
menopause: a meta-analysis. Menopause. 2015; 1; 22(4):469-74. 
9. Akahoshi M, Soda M, Nakashima E, et al. The effects of body mass index on age at 
menopause. Int J Obes Relat Metab Disord. 2002; 26:961–8. 
10. FORNEY JP, MILEWICH L, CHEN GT, GARLOCK JL, SCHWARZ BE, EDMAN 
CD, MACDONALD PC. Aromatization of Androstenedione to Estrone by Human 
Adipose Tissue in Vitro. Correlation with Adipose Tissue Mass, Age, and Endometrial 
Neoplasia. J  Clinl Endoc & Metab. 1981; 53(1):192-9. 
11. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on 
conversion of plasma androstenedione to estrone in postmenopausal women with and 
without endometrial cancer. Am J Obstet Gynecol. 1978 Feb 15; 130(4):448-55. 
12. Leidy LE. Timing of menopause in relation to adiposityand weight change. Hum Biol 
1996; 68:967–82. 
13. Hardy R, Mishra GD, Kuh D. Body mass index trajectories and age at menopause in a 
British birth cohort. Maturitas. 2008; 59(4):304–314. 
14. Gold EB, Crawford SL, Avis NE, Crandall CJ, Matthews KA, Waetjen LE, Lee JS, 
Thurston R, Vuga M, Harlow SD. Factors related to age at natural menopause: 
longitudinal analyses from SWAN. Am J Epidemiol2013; 178(1):70-83. 
15. Aydin ZD. Determinants of age at natural menopause in the Isparta Menopause and 
Health Study: premenopausal body mass index gain rate and episodic weight loss. 
Menopause. 2010; 17(3):494–505. 
16. Morris DH, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ. Body 
mass index, exercise, and other lifestyle factors in relation to age at natural menopause: 
 31  
analyses from the breakthrough generations study. Am J Epidemiol. 2012 15; 
175(10):998-1005. 
17. Kok HS, van Asselt KM, van der Schouw YT, et al. Heart disease risk determines 
menopausal age rather than the reverse. J Am Coll Cardiol. 2006; 47:1976-1983. 
18. Gold EB, Crawford SL, Shelton JF, Tepper PG, Crandall CJ, Greendale GA, Matthews 
KA, Thurston RC, Avis NE. Longitudinal analysis of changes in weight and waist 
circumference in relation to incident vasomotor symptoms: the Study of Women's Health 
Across the Nation (SWAN). Menopause. 2017; 24(1):9-26. 
19. Szegda KL, Whitcomb BW, Purdue-Smithe AC, Boutot ME, Manson JE, Hankinson SE, 
Rosner BA, Bertone-Johnson ER. Adult adiposity and risk of early menopause. Hum 
Reproduc. 2017 25; 32(12):2522-31. 
20. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and 
some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116. 
21. Research on the menopause in the 1990s. Report of a WHO Scientific Group. World 
Health Organization technical report series. [TechnicalReport] 1996;866:1-107 
22. Norman JE, Bild D, Lewis CE, Liu K, West DS. The impact of weight change on 
cardiovascular disease risk factors in young black and white adults: the CARDIA study. 
Int J Obes Relat Metab Disord, 2003; 27: 369–76. 
23. Anderssen N, Jacobs DR Jr, Sidney S, et al. Change and secular trends in physical 
activity patterns in young adults: a seven-year longitudinal follow-up in the Coronary 
Artery Risk Development in Young Adults Study (CARDIA). Am J Epidemiol.1996; 
143(4):351-362. 
24. Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension during young 
adulthood and coronary calcium later in life. Ann Intern Med 2008; 149:91-99. 
25. Gunderson EP, Jacobs DR Jr, Chiang V, et al. Duration of lactation and incidence of the 
metabolic syndrome in women of reproductive age according to gestational diabetes 
mellitus status: a 20-year prospective study in CARDIA (Coronary Artery Risk 
Development in Young Adults). Diabetes. 2010; 59(2):495-504. 
26. Bild DE, Jacobs DR, Liu K, et al. Seven-year trends in plasma low-density-lipoprotein-
cholesterol in young adults: the CARDIA Study. Ann Epidemiol. 1996; 6(3):235-245. 
27. Hardy R, Kuh D, Wadsworth M. Smoking, body mass index, socioeconomic status and 
the menopausal transition in a British national cohort. Int J Epidemiol. 2000; 29:845–51. 
28. Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas. 2000; 
35:3–9. 
29. Cooper GS, Baird DD, Darden FR. Measures of menopausal status in relation to 
demographic, reproductive, and behavioral characteristics in a population-based study of 
women aged 35–49 years. Am J Epidemiol. 2001; 153(12):1159–1165. 
30. Jasienska G, Ziomkiewicz A, Thune I, et al. Habitual physical activity and estradiol 
levels in women of reproductive age. Eur J Cancer Prev 2006; 15:439–445.  
31. Poehlman ET, Toth MJ, Bunyard LB, et al. Physiological predictors of increasing total 
and central adiposity in aging men and women. Arch Intern Med. 1995; 155(22):2443-
2448. 
32. Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. Hum Reprod 
Update. 2017; 23(3):300-321. 
 32  
33. Douchi T, Yamamoto S, Yoshimitsu N, Andoh T, Matsuo T, Nagata Y. Relative 
contribution of aging and menopause to changes in lean and fat mass in segmental 
regions. Maturitas.2002; 42(4):301-306. 
34. Gallicchio L, Miller SR, Kiefer J, Greene T, Zacur HA, Flaws JA. Change in body mass 
index, weight, and hot flashes: a longitudinal analysis from the midlife women's health 
study. J Women's Health. 2014; 23(3):231-7. 
35. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, 
regional, and global trends in body-mass index since 1980: systematic analysis of health 
examination surveys and epidemiological studies with 960 country-years and 9.1 million 
participants. Lancet. 2012; 377(9765):557±67. 
36. Johnson W, Li L, Kuh D, Hardy R. How Has the Age-Related Process of Overweight or 
Obesity Development Changed over Time? Co-ordinated Analyses of Individual 
Participant Data from Five United Kingdom Birth Cohorts. PLoS Med. 2015; 
12(5):e1001828.  
37. Lim HS, Kim TH, Lee HH, Park YH, Kim JM, Lee BR. Hypertension and age at onset of 
natural menopause in Korean postmenopausal women: results from the Korea National 
Health and Nutrition Examination Survey (2008–2013). Maturitas. 2016; 90:17-23. 
38. Ebong IA, Schreiner P, Lewis CE, Appiah D, Ghelani A, Wellons M. The association 
between high-sensitivity C-reactive protein and hypertension in women of the CARDIA 
study. Menopause. 2016; 23(6):662-8. 
39. Bojar I, Gujski M, Raczkiewicz D, Łyszcz R, Owoc J, Walecka I. Estrogen receptor 
alpha polymorphisms, estradiol level, and occurrence of atherosclerosis risk factors in 
healthy postmenopausal women. Med Sci Monit. 2015; 21:970-9. 
40. Giordano S, Hage FG, Xing D, Chen YF, Allon S, Chen C, et al. Estrogen and 
cardiovascular disease: is timing everything? Am J Med Sci. 2015; 350:27-35. 
41. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the 
metabolic syndrome: the Study of Women's Health Across the Nation. Arch Int Med. 
2008; 168(14):1568-75. 
42. Martin LJ, Greenberg CV, Kriukov V, et al. Intervention with a low-fat, high-
carbohydrate diet does not influence the timing of menopause. Am J Clin Nutr. 2006; 
84:920–928.  
43.  Torgerson DJ, Avenell A, Russell IT, et al. Factors associated with onset of menopause 
in women aged 45-49. Maturitas 1994; 19:83–92.  
44. Nagata C, Takatsuka N, Kawakami N, et al. Association of diet with the onset of 
menopause in Japanese women. Am J Epidemiol 2000; 152:863–867.  
45. Nagel G, Altenburg HP, Nieters A, et al. Reproductive and dietary determinants of the 
age at menopause in EPIC-Heidelberg. Maturitas 2005; 52:337–347.  
46. Boutot ME, Purdue-Smithe A, Whitcomb BW, Szegda KL, Manson JE, Hankinson SE, 
Rosner BA, Bertone-Johnson ER. Dietary Protein Intake and Early Menopause in the 
Nurses’ Health Study II. Am J Epidemiol. 2017.  
47. MacInnis RJ, Hodge AM, Dixon HG, Peeters A, Johnson LE, English DR, Giles GG. 
Predictors of increased body weight and waist circumference for middle-aged adults. 
Public Health Nutr. 2014; 17(5):1087-97. 
48. Dalvand S, Koohpayehzadeh J, Karimlou M, Asgari F, Rafei A, Seifi B, Niksima SH and 
Bakhshi E. Assessing factors related to waist circumference and obesity: application of a 
latent variable model. J Environ Publ Health, 2015. 
 33  
49. Lang T, Lepage B, Schieber AC, Lamy S and Kelly-Irving M, Social determinants of 
cardiovascular diseases. Publ Health Reviews, 2011, 33(2). 
50. Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer 
FE. Reproducibility and validity of self-reported menopausal status in a prospective 
cohort study. Am J Epidemiol. 1987; 126(2):319-25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34  
 
Chapter 3 
Age at natural menopause (ANM) and its associated factors in Canada: Cross-sectional 
Analyses from the Canadian Longitudinal Study on Aging (CLSA) 
 
Abstract 
Background: Early onset of menopause is associated with long term disease and higher 
mortality risks. Research suggests that age at natural menopause (ANM) varies across 
populations. Little is known about factors that affect ANM in Canadian women. 
Objective: This study aims to estimate the median ANM and examine factors associated with 
earlier ANM among Canadian women.  
Methods: Baseline data from the Tracking cohort of the Canadian Longitudinal Study on Aging 
(CLSA) were used for this analysis. The relation of sociodemographic, lifestyle and health 
related factors with ANM was examined among 7,719 women aged 40 and above. 
Nonparametric Kaplan–Meier cumulative survivorship estimates were used to assess the timing 
of natural menopause. Univariate and multivariate Cox proportional hazard regression models 
were used to characterize ANM and its association with relevant covariates. 
Results: Overall, median ANM was 51 years.  Having no partner, low household income and 
education levels, current and former smoking, and cardiovascular disease (CVD) were all 
associated with an earlier ANM, while current employment, alcohol consumption, and obesity 
were associated with later ANM.  
Conclusion: These findings provide a national estimate of ANM in Canada.  These findings 
show the importance of lifestyle factors and health conditions in determining menopausal age. 
These factors might help in risk assessment, prevention and early management of chronic disease 
risk during the menopausal transition.  
 
Keywords: Menopause, Factors, Smoking, Education, Weight, Canada 
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3.1 Introduction  
 
 While secular changes in the average ANM are not as well documented as those as the 
age of menarche, there is some evidence to suggest that there have been increases in the  average 
age at menopause in the past century1,2. Contemporary industrialized populations demonstrate a 
later mean age at menopause than non-industrialized populations3. The median age of 
menopause in Western countries is between 48 and 52 years4.  However, the median age range of 
menopause in developing countries is between 47 to 49.3 years5. A recent meta-analysis of 36 
studies across the globe (excluding Canada) on the age of menopause resulted in an overall 
median age of 48.7 years6.  Distribution by geographical region demonstrated that ANM was 
generally lower among African, Latin American, Asian and Middle Eastern countries and was 
highest in Europe and Australia, followed by the USA6. Moreover, ANM also varies by 
race/ethnicity. In fact, Palmer et al7 found that African American women have an earlier onset of 
ANM than Caucasian women. Therefore, natural menopause is a complex biosocial and bio 
cultural phenomenon with geographic and ethnic variations.  
 
Previous studies have shown that variation in age of menopause is associated with several 
factors such as genetic, reproductive, demographic and lifestyle behaviors. ANM has been 
positively associated with maternal age at menopause and twin studies have found a significant 
heritability of ANM8. Earlier age of menopause has also been associated with nulliparity, 
cigarette smoking, lower socioeconomic status and education levels, unemployment, single 
marital status, non-oral contraceptive (OC) use, and low body mass index (BMI) as reported in a 
review on the correlates of ANM8.  However, the majority of these results remain inconsistent 
across studies. With the increase in life expectancy, the proportion of postmenopausal life also 
increases. Thus, the impact of menopause on women’s health has become more significant from 
both clinical and public health perspectives. The age at which menopause occurs is critical for 
women’s health trajectory, as it is an indicator of ovarian function and aging, and portends future 
health risks. Women with an earlier menopause are at an increased risk of cardiovascular disease 
(CVD) and osteoporosis, while women with a later menopause are at an increased risk of breast 
and endometrial cancers8, 11.  
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Menopause, one of the major components of women’s reproductive lives, is not only 
understood as being integral to women’s overall health and wellbeing, but is increasingly 
recognized as a sentinel of chronic disease in later life. Factors that influence age at menopause 
may affect not only timing of cessation of menses but also future cardiovascular and 
reproductive health outcomes. A definition of the factors related to ANM is warranted as a 
means for quantifying risk for earlier or later menopause as a number of gaps in our 
understanding of preventable factors that may influence ANM exist. No study to date has 
provided a nationally representative estimate of the ANM in Canada and has directly examined 
the correlates of age at menopause. Therefore, this study aims to investigate the correlates of 
ANM among a population- based, nationally representative sample of Canadian women. 
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3.2 Methods 
Study Design and Sample 
Baseline data from the Tracking cohort (version 3.0) of the Canadian Longitudinal Study 
on Aging (CLSA) were accessed for secondary analysis. In short, the CLSA is a 20 year 
prospective study of 50,000 men and women aged between 45 and 85 years at baseline. 
Launched in 2010, the CLSA aims to provide national-level insight into the behaviors and health 
of adults ages 45 to 85 years at baseline. The study has two categories of participants: i) the 
Tracking cohort who were randomly selected within age and sex strata in each province and 
followed by telephone interview, and; ii) the Comprehensive cohort participants, who had more 
intensive physical measures as well as questionnaire surveys. The Tracking cohort included 
n=21,241 (males: 10,406; females: 10,835) non-institutionalized participants distributed across 
all 10 provinces. Individuals living in long-term care institutions, and having cognitive 
impairment at the time of recruitment were excluded at baseline. However, those living in 
households and transitional housing arrangements (e.g., seniors’ residences, in which only 
minimal care is provided) were included. The CLSA study design has been previously described 
in detail elsewhere9.  
 
Study Participants  
Of the initial overall sample that included 10,835 women, 449 women who had 
undergone menopause before 40 years of age were excluded (4.1% of overall sample) since 
premature ovarian failure has a different etiology than typical menopause and this exclusion also 
has the effect of preventing underestimation of a true ANM10.  Women who reported undergoing 
menopause after age 62 were also excluded12, as were women who did not experience 
menopause by age 62 (0.79% of overall sample) because some women might have pathologic 
conditions resulting in very late menopause or these values could be inaccurate11. Women 
diagnosed with breast, ovarian, or endometrial cancers (23% of overall sample) were excluded 
from the analysis since treatment for these female cancers includes hormone use, which might 
mask the true age of menopause13, 14. Women were also excluded if they had undergone surgical 
menopause by means of a hysterectomy (14.8% of overall sample) as their menopausal status is 
unclear; whilst it would have been legitimate to include women who had a hysterectomy in this 
analysis, no information on the age at which this surgery was performed had been collected. 
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Women who had missing information on ANM were also excluded. After these exclusions 
(28.8% of overall sample), 7,719 women remained for analysis as seen in Figure 1. 
 
Assessment of Outcome 
Menopausal status was assessed by asking the following question: “Have you gone 
through menopause, meaning that your menstrual periods stopped for at least one year and did 
not restart?” Women who answered “yes” were classified as naturally post-menopausal. Age at 
natural menopause is defined as the age of last menses, occurring after at least 12 months of 
amenorrhea as per the WHO’s definition. Individual age at natural menopause, the primary 
outcome of this analysis, was reported in response to the following question: “How old were you 
when your menstrual periods stopped for at least one year and did not re-start?” Answers were 
recorded as age in years. Age at menopause was defined in this analysis as a continuous variable 
taking into consideration women who did not attain menopause at the time of outcome 
assessment. Self-reported age at menopause has shown in previous studies to have showed high 
validity and reliability, with over 70% of women recalling their age at menopause to within one 
year, after a time span of 7 years since asked, and an overall Spearman’s correlation coefficient 
of 0.8716.  
 
Covariates    
Sociodemographic variables included age at time of interview, ethnicity classified as 
white, aboriginal, and mixed/other, where “other” included non-white ethnic groups such as 
South Asian, Chinese, Hispanic, Arab, and Black. Additional sociodemographic information 
included highest education level (less than high school, high school to some college, Bachelor’s 
degree or higher), marital status (partner vs. no partner), current employment status, and annual 
household income in CAD (<20,000, 20,000-50,000, 50,000-100,000, >100,000).  Lifestyle 
factors included smoking status (never, former, or current), alcohol consumption (never, less 
than weekly, at least weekly), and frequency of leisure time physical activity in the past year 
(regular vs. non-regular) with regular physical activity defined as those who participated in 
leisure time physical activity at least once a day. Clinical variables included self-reported status 
of type 2 diabetes, hypertension, CVD, mood disorders, anxiety disorders, and presence of any 
allergies. Height and weight were also reported and were used to calculate BMI in kg/ m2. A cut-
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off of 20kg/m2 was used for a BMI of underweight instead of 18.5 kg/m2, because most of the 
women in this sample were older (45 and over), and so are less likely to be very underweight12,20. 
 
Endpoints 
ANM was the main outcome, but the analysis method allowed premenopausal women to 
contribute person-years even if they did not reach natural menopause during the study period. 
Women who did not experience menopause were considered as censored observations (20.9% of 
overall sample). Endpoint age was defined as one of the following: a) age at natural menopause 
for postmenopausal women, b) age at interview if a woman was premenopausal, c) age at HRT 
initiation among women who had used HT prior to menopause. 
 
Statistical Analysis 
Nonparametric Kaplan–Meier cumulative survivorship estimates were used to assess the 
median ANM. The Kaplan–Meier method may be applied to cross-sectional data by using age 
rather than time as the censoring variable19, 20. Unadjusted and adjusted Cox proportional hazard 
regression models were then used to estimate the associations of ANM with the independent 
variables. Hazard ratios (HR’s) and their confidence intervals (CI’s) for earlier age at menopause 
were estimated. Exposures with HR’s greater than 1 were associated with earlier onset of 
menopause, and those with HR’s less than 1 were associated with later age at menopause. 
Validity of the proportional hazards assumption was checked by log-log plots with most 
variables not violating the assumption with the exception of: household income, smoking status, 
and CVD status. However, upon close inspection of the plots, the curves were close to parallel, 
with a minimal effect on the interpretation of the results (Appendix B). Moreover, based on prior 
research those variables were important factors, therefore the model was left unaltered. Goodness 
of fit of the multivariate Cox model was also assessed using the likelihood ratio test and Cox-
Snell residuals to create the Nelson-Aalen cumulative hazard function (Appendix B). Our data 
overall followed an exponential distribution indicating that our model fits the data well21. Inverse 
probability weights (inflation and analytic weights) were used to account for the complex 
sampling method as per the guidelines set by CLSA. A p-value < 0.05 was considered 
statistically significant. All statistical data analyses were carried out using STATA version 12. 
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3.3 Results 
 
Table 1 shows descriptive characteristics of the 7,719 women (weighted N= 5,065,656) 
included in this analysis. Their mean age at interview was 61.7 years (SD=10.6). Natural 
menopause was reported by 72.7% (weighted N= 3,675,924) of women. The majority of women 
in the sample were White (93%), and with partner (68.3%).  Over 50% of women had a high 
school to some college education, were not currently employed, and over a quarter had a 
household income between 50,000-100,000 CAD. The proportion of women who had never 
smoked was 35.1%, while 54.5% were former smokers. Almost 50% of women consumed 
alcohol at least weekly, and over half performed leisure time physical activity on a regular basis 
in the past year. Around 70% of women in the sample had never used hormone therapy (HT). 
The proportion of women whose BMI was considered normal weight was 41.1%, whereas 30% 
of women were overweight and 22% were obese. Over a quarter of women reported to have 
hypertension, while less than 15% reported having type 2 diabetes or CVD, respectively.  Figure 
2 shows the distribution of their reported menopausal ages (Kaplan-Meier median age: 51 years; 
mean age: 49.9 years, range: 40–62 years).  Table 2 outlines results of the unadjusted and 
adjusted Cox regression analysis. The multivariate model showed that women with no partner 
(HR= 1.09, 95%CI=1.02-1.17), with high school to some college level education (HR=1.13, 
95%CI=1.06-1.21); women whose household income was between 20,000-50,000 CAD were at 
an increased risk of having an earlier natural menopause versus their counterparts. Current 
smokers had a greater hazard (HR=1.34, 95%CI=1.19-1.50) of having an earlier natural 
menopause than never smokers. Women who had CVD (HR=1.12, 95%CI=1.00-1.24) were also 
at a higher risk of having an earlier natural menopause than their counterparts. On the contrary, 
women who were currently employed (HR=0.84, 95%CI=0.79-0.90), who consumed alcohol at 
least weekly (HR=0.89, 95%CI=0.81-0.98) or less than weekly (HR=0.90, 95%CI=0.82-0.98) 
were more likely to have a later age at natural menopause. Moreover, women who were obese 
(HR=0.89, 95%CI=0.82-0.96) were more likely to have a later menopause than normal weight 
women in the multivariate model.  
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3.4 Discussion 
 
This study aimed to identify the median ANM and investigate the characteristics 
affecting ANM among women in Canada.  Median ANM was 51 years, as per the Nonparametric 
Kaplan–Meier cumulative survivorship estimates. Results of the multivariate analysis revealed 
associations between marital status, household income, education level, employment, smoking 
status, drinking habits, BMI, and CVD with age at onset of menopause. Elucidating the median 
age of menopause in a population is of clinical relevance given the potential adverse health 
outcomes associated with an earlier or later menopause. Identifying modifiable factors of ANM 
would thus impact etiological research on, and prevention of, these chronic diseases.  
 
The results obtained by the Kaplan–Meier cumulative estimate indicated that overall 
median age at menopause was 51 years, which is similar to that found in previous studies16, 20, 22.  
The median age at menopause in Canada was similar to Australia23, The Netherlands24, and 
Greece25, but was one year lower than that found by the most recent analysis from the US based 
Study of Women’s Health across the Nation (SWAN) cohort26. Moreover, Schoenaker et al6, in a 
meta-analysis of ANM that included 36 studies, found a mean ANM ranging from 46 to 52 
years.  ANM varied between geographical regions with African, Latin American, Asian and 
Middle Eastern countries having a lower ANM, while Europe, Australia, and USA having a 
higher ANM. 
 
These large data provide evidence that socioeconomic conditions are key factors related 
to ANM, a finding consistent with previously published results7, 8, 15, 27, 28. Indeed, a meta-
analysis including worldwide studies showed that lower education level and low occupation 
status were significantly associated with earlier ANM6. Employment, education, and income 
level are indicators of perceived economic security as well as social and emotional stress29. It has 
been suggested that psychological stress affects ovarian function and, therefore, age at 
menopause by lowering telomerase activity, a cellular enzyme that may act as a marker of 
ovarian age via its association with follicular atresia29. Physiological stress responses such as that 
of the hypothalamic-pituitary-adrenal axis, on the other hand, may also influence ANM30. 
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Our results indicated that women without a partner were more at risk of having an earlier 
ANM compared to women with partner. Marital status has not been consistently measured in 
previous studies, with the exception of Gold et al22, therefore not many explanations exist for this 
observed association. However, parity, a possible proxy indicator for marital status, has been 
consistently associated with older age at menopause8. Mishra et al31 in a pooled study that 
consisted of 51,450 postmenopausal women from nine observational studies in the UK, 
Scandinavia, Australia and Japan, found that nulliparous women were at a significantly increased 
risk of early menopause (RR=1.32, 95%CI=1.09–1.59). This relationship provides support to the 
hypothesis that the rate of depletion of oocytes influences the age at menopause with increasing 
number of children delaying age at menopause8, 22. 
 
Prior studies have consistently shown that current smoking is associated with an earlier 
menopause1, 6, 8-18, 22-26, as was observed in our study. Polycyclic aromatic hydrocarbons in 
cigarette smoke are non-reversibly toxic to ovarian follicles32, thereby accelerating the onset of 
menopause by reducing circulating estrogen. Former smokers were also found to be at an 
increased risk of earlier menopause than never smokers. ANM in ex-smokers was rarely reported 
across studies6, 33, with Schoenaker et al6 reporting no difference in ANM between former and 
non-smokers. This study also indicated that alcohol consumption is associated with later onset of 
menopause. A positive association between alcohol consumption and ANM has previously been 
noted in the United Kingdom11 and United States 8,10,14,22,26,34,35, but reports from other countries, 
including China, Norway, and Germany, have shown no association20, 36-39. Taneri et al40 in a 
recent meta-analysis of 22 articles found that in prospective studies, a low-to-moderate alcohol 
intake (0–8 g/day (RR = 0.95; 95% CI: 0.93–0.98), and 16 g/day (RR = 0.89, 95%CI: 0.86–0.92) 
was associated with a later menopause. An explanation for this finding is that moderate alcohol 
consumption increases estrogen levels in premenopausal women41.  
 
The association of higher BMI with later ANM found in this study is in concordance with 
previous studies13, 24, 26, 36. However, the effect of BMI on age at menopause remains vague with 
other studies finding no association between BMI and ANM14, 18, 22. It is hypothesized that 
increased estrone production in the adipose tissue of obese women might delay menopause 
onset42. Estrone is formed by the peripheral aromatization of androgens, namely 
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androstenedione, which is secreted by the ovaries and/or adrenal glands43. The conversion of 
androgens into estrone has been linked to an increase in body weight44. On the other hand, since 
obesity has also been associated with inadequate ovarian function, it may be a determinant of 
earlier menopause45.  An explanation to this observation might lie in that caloric restriction and 
nutritional deficiencies in both primates and humans are associated with amenorrhea46.  
 
Many chronic diseases have been linked to menopause onset47-49. Our results showed that 
women with a CVD diagnosis were at an increased risk of earlier menopause. This finding is 
interesting since comorbid health conditions such as CVD were not extensively assessed in 
relation to ANM in previous studies16, 22. The relationship and direction between CVD risk 
factors and outcomes vis a vis ANM is not clear. CVD could be a risk factor for ANM as shown 
in this study, which is consistent with Gold et al22. CVD risk factors such as total cholesterol 
(TC), low-density lipoprotein cholesterol (LDL-c) levels, and systolic and diastolic blood 
pressure levels may be associated with menopausal status independent of age as de Kat and 
colleagues50 found.  Moreover, Kok et al51, using data from the Framingham Heart Study cohort, 
showed that each 1% increase in the Framingham risk score pre-menopause was significantly 
associated with a 1.8 year decrease in ANM. Yet, CVD could also be an outcome of earlier 
ANM52, 54.  Further research is needed to confirm the association between CVD and ANM, 
however. One mechanism through which menopause might affect CVD lies in estrogen 
deficiency. Estrogen is thought to protect against CVD and its risk factors in premenopausal 
women via both systemic and local vascular effects as it has been shown to lower LDL 
cholesterol and increase HDL cholesterol53, 54. After menopause, estrogen deficiency may lead to 
rapid increases in blood pressure55 and vascular injury 56.  
 
This study had several strengths. It is the first study to obtain a robust median estimate as 
well as the correlates of ANM in Canada using a large and nationally representative sample of 
participants. Furthermore, the simultaneous adjustment of multiple factors in the Cox model, 
while censoring at initiation of hormone therapy, limited the potential for confounding bias due 
to HRT use. Nonetheless, a few limitations exist. One, the cross-sectional nature of the study 
precludes the inference of causality. Recall bias due to self-report of ANM might be another 
limitation. Although all cases with chronic diseases were diagnosed by a physician, these 
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diagnoses were not confirmed by more objective medical procedures. In addition, most of the 
data were derived from questionnaires based on memory recall. Data on oral contraceptive use, 
breastfeeding, age at menarche, and early life circumstances- factors that have been previously 
linked to age at menopause- were not collected. Lastly, the exclusion of women with surgical 
menopause and breast cancer might affect the generalizability of our findings.  
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3.5 Conclusion 
 
This study constitutes the first nation-wide study of the onset of natural menopause in 
Canadian women. The overall median ANM was 51 years. This study’s findings revealed that 
the ANM reflects the complex intertwining of social determinants, lifestyle factors and health 
conditions.  Since ANM is a risk factor for a number of disorders, understanding factors 
associated with menopausal age is integral to identify menopausal women who are at high risk 
for future morbidity. CVD status was significantly associated with ANM highlighting the 
importance of both control and prevention of CVD risk factors during the menopausal transition. 
Prospective studies are required to determine the causal association between chronic conditions, 
such as CVD, as well as lifestyle factors and ANM. The evidence provided here also emphasizes 
early preventive strategies and clinical surveillance of chronic diseases for women in the 
menopause transition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46  
 
Figure 3.1: CLSA participants’ flowchart 
7,719 women included in sample 
 
Censoring events: 
 1,704 Pre-menopausal women 
 443 HRT age< ANM 
 
10,835 women recruited in CLSA Tracking 
cohort 
Exclusions: 
 1,818 surgical menopause 
 636  female cancer diagnosis 
 128 did not report ANM 
 449 ANM<40 years 
 23 ANM>62 years 
 62 women who did not attain 
menopause by age 62 
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Figure 3.2: Kaplan–Meier cumulative estimates of ANM in Canadian women. 
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Table 3.1: Baseline characteristics of women in the CLSA by menopause status. 
 Total Sample  
 
Natural 
Menopause 
Median age at natural 
menopause, years (IQR)c 
Variables Na   (%) N   (%)b  
Sociodemographic      
Ethnicity        
  White(non-aboriginal) 4,613,943 93.0 5,163 73.3 51(49-54) 
   Aboriginal 145,446 2.90 150 63.6 51(49-55) 
  Mixed/other 201,149 4.05   160 65.7 51(49-54) 
Marital Status       
   No partner 1,583,493 31.5 1,970 82.2 50(48-54) 
   With partner 3,449,925 68.5 3,599 68.3 52(50-55) 
Education Level       
   Less than high school 381,148 7.60   428 75.8 51(49-55) 
   High school to some 
college 
2,776,595 55.2 3,270 75.9 51(48-54) 
   Bachelor’s degree or higher 1,875,833 37.3 1,867 67.0 52(50-55) 
Employment Status       
   Not currently working 2,648,432 52.6 3,630 90.0 51(48-54) 
   Currently working 2,385,104   47.4 1,939 53.5 52(50-55) 
Household Income (CAD)      
<20,000 273,551 5.80 378 88.6 50(47-53) 
20,000-50,000 1,176,701 25.1 1,615 86.7 51(48-54) 
50,000-100,000 1,619,610   34.6 1,841 74.5 52(49-55) 
>100,000 1,614,550 34.5 1,240 53.6 52(50-55) 
Lifestyle      
Smoking Status       
   Never 1,760,239 35.1 1,896 70.3 52(50-55) 
   Former 2,750,097 54.9 3,084 74.2 52(49-55) 
   Current 500,040 10.0 562 72.2 50(47-53) 
 Alcohol consumption       
Never 655,846 13.0 888 80.4            50(48-54) 
Drinks less than weekly 1,829,020 36.4 2,118 71.6 51(49-55) 
Drinks at least weekly 2,544,592 50.6 2,557 71.0 52(49-55) 
Leisure time physical 
activity  
     
    Non-regular 2,237,806 44.5 2,629 74.9 51(49-54) 
    Regular  2,789,076   55.5  2,927 70.6 52(49-55) 
HT use       
    Never 3,558,393 70.9 3,561 65.1 52(50-55) 
    Ever 1,463,020 29.1 1,995 91.5 50(48-54) 
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Table 3.1 (Cont’d):  Baseline characteristics of women in the CLSA by menopause status. 
Health  related       
BMI (Kg/m2)      
20.0-24.99 (normal weight) 2,080,942   41.7 2,142 70.1 51(49-54) 
<20.00 (underweight) 322,450 6.50 336 71.9 50(49-54) 
25.0-29.99 (overweight) 1,502,085 30.1 1,782 75.8 51(49-55) 
> 30.0 (obese) 1,081,789 21.7 1,268 73.3 52(49-55) 
Hypertension       
    No 3,565,264 70.9 3,626 67.1 52(49-55) 
   Yes 1,464,920 29.1 1,938 85.6 51(48-54) 
Diabetes       
    No  4,432,514 88.1 4,812 71.4 51(49-55) 
    Yes  599,739  11.9 753 81.4 51(48-54) 
Cardiovascular disease      
    No  4,610,836 91.7 5,026 71.2 51(49-55) 
    Yes  415,695 8.30 530 88.5 50(47-53) 
Allergies      
No 2,853,193    56.8 3,193 73.4 51(49-54) 
Yes 2,171,697 43.2 2,362 71.6 52(49-55) 
Mood Disorders       
   No 4,146,876 82.4 4,606 72.7 51(49-54) 
   Yes 885,077 17.6 961 72.1 51(49-54) 
Anxiety Disorders       
    No 4,562,525  90.7 5,084 73.0 51(49-54) 
    Yes 466,394 9.30 483 69.1 51(49-55) 
Abbreviations: IQR, interquartile range. 
a Sample size is estimated using inflation weights; figures not always sum up to the total due to missing values.  
b Frequencies are column percentages estimated using analytic weights. 
C Calculated using Kaplan-Meier estimate 
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Table 3.2: Unadjusted and adjusted hazard ratios (HR’s) for age at natural menopause (ANM).  
 Unadjusted Hazard Ratio Adjusted Hazard Ratio 
Variables   
Sociodemographic HR(95%CI) HR(95%CI) 
Ethnicity     
   Aboriginal 1.13(0.95-1.35) 1.03(0.85-1.23) 
  Mixed/other 1.11(0.93-1.32) 1.17(0.96-1.41) 
  White 1.00 1.00 
Marital Status    
  No partner 1.21(1.14-1.28) 1.09(1.02-1.17) 
Education Level    
   Less than high school 1.07(0.96-1.20) 1.02(0.91-1.15) 
   High school to some college 1.20(1.13-1.27) 1.13(1.06-1.21) 
   Bachelor’s degree or higher 1.00 1.00 
Employment Status    
   Currently working 0.80(0.75-0.85) 0.84(0.78-0.90) 
Household Income (CAD)   
<20,000 1.50(1.32-1.70) 1.10(0.95-1.28) 
20,000-50,000 1.36(1.25-1.47) 1.14(1.04-1.25) 
50,000-100,000 1.18(1.09-1.28) 1.10(1.01-1.19) 
>100,000 1.00 1.00 
Lifestyle   
Smoking Status    
   Never 1.00 1.00 
   Former 1.05(0.99-1.12) 1.07(0.99-1.14) 
   Current 1.42(1.27-1.57) 1.34(1.19-1.50) 
 Alcohol consumption    
Never 1.00 1.00 
Drinks less than weekly 0.88(0.81-0.95) 0.90(0.82-0.98) 
Drinks at least weekly 0.85(0.78-0.92) 0.89(0.81-0.98) 
Leisure time physical activity    
    Regular  1.09(1.03-1.15) 1.03(0.97-1.10) 
Health  related    
BMI (Kg/m2)   
20.0-24.99 (normal weight) 1.00 1.00 
<20.00 (underweight) 1.15(1.02-1.30) 1.13(0.99-1.30) 
25.0-29.99 (overweight) 0.99(0.92-1.06) 0.94(0.87-1.01) 
> 30.0 (obese) 0.96(0.90-1.04) 0.89(0.82-0.96) 
Hypertension    
   Yes 1.12(1.06-1.19) 1.06(0.99-1.13) 
Diabetes   
    Yes  1.08(0.99-1.18) 0.98(0.89-1.07) 
Cardiovascular disease   
    Yes  1.23(1.12-1.36) 1.12(1.00-1.24) 
Allergies   
Yes 0.96(0.91-1.02) 0.99(0.94-1.05) 
Mood Disorders    
   Yes 1.02(0.94-1.96) 1.02(0.94-1.11) 
Anxiety Disorders    
    Yes 0.98(0.88-1.08) 0.92(0.82-1.04) 
 
 
 51  
 
References: 
1. Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas 2000; 
35:3-9. 
2. Dratva J, Gomez Real F, Schindler C, et al. Is age at menopause increasing across 
Europe? Results on age at menopause and determinants from two population-based 
studies Menopause 2009; 16:385-394. 
3. Thomas F, Renaud F, Benefice E, de Meeu¨ s T, Guegan JF. International variability of 
ages at menarche and menopause: patterns and main determinants. Hum Biol 2001; 
73:271-290. 
4. Mishra GD, Cooper R, Tom SE, Kuh D. Early life circumstances and their impact on 
menarche and menopause. Womens Health (Lond) 2009; 5:175-190. 
5. Reynolds RF, Obermeyer CM. Age at natural menopause in Spain and the United States: 
results from the DAMES project. Am J Hum Biol 2005; 17:331-340. 
6. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, 
lifestyle factors and age at natural menopause: a systematic review and meta-analyses of 
studies across six continents. Int J Epidemiol 2014; 43:1542-1562. 
7. Palmer JR, Rosenberg L, Wise LA, Horton NJ, Adams-Campbell LL. Onset of natural 
menopause in African American women. Am J Public Health 2003; 93:299-306. 
8. Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin 
North Am 2011; 38:425-440. 
9. Whelan EA, Sandler DP, McConnaughey DR, Weinberg CR. Menstrual and 
reproductive characteristics and age at natural menopause. Maturitas 1990; 131:625-632. 
10. Raina PS, Wolfson C, Kirkland SA, et al. The canadian longitudinal study on aging 
(CLSA). Can J Aging 2009; 28:221-229. 
11. Sievert LL, Hautaniemi SI. Age at menopause in Puebla, Mexico. Hum Biol 2003; 
75:205-226. 
12. Morris DH, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ. Body 
mass index, exercise, and other lifestyle factors in relation to age at natural menopause: 
analyses from the beakthrough generations study. Am J Epidemiol 2012; 175:998-1005. 
13. Yasui T, Hayashi K, Mizunuma H, et al. Factors associated with prema- ture ovarian 
failure, early menopause and earlier onset of menopause in Japanese women. Maturitas 
2012; 72:249-255. 
14. Bromberger JT, Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. 
Prospective study of the determinants of age at menopause. Am J Epidemiol 1997; 
145:124-133. 
15. den Tonkelaar I. Validity and reproducibility of self-reported age at menopause in 
women participating in the DOM-project. Maturitas 1997; 27:117-123. 
16. Kaczmarek M. The timing of natural menopause in Poland and associated factors. 
Maturitas 2007; 57:139-153. 
17. Cramer DW, Xu H. Predicting age at menopause. Maturitas 1996; 23: 319-326. 
18. Survival analysis with STATA: Goodness of fit of final model. UCLA: Statistical 
Consulting Group. Available at: https://stats.idre.ucla.edu/stata/seminars/stata-
survival/#fit. Accessed April 20, 2017. 
19. Ortiz AP, Harlow SD, Sowers M, Nan B, Romaguera J. Age at natural menopause and 
factors associated with menopause state among Puerto Rican women aged 40-59 years, 
living in Puerto Rico. Menopause 2006; 13:116-124. 
20. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural 
 52  
menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153:865-
874. 
21. Do KA, Treolar SA, Pandeya N, et al. Predictive factors of age at menopause in a large 
Australian twin study. Hum Biol 1998; 70:1073-1091. 
22. de Vries E, den Tonkelaar I, van Noord PA, van der Schouw YT, te Velde ER, Peeters 
PH. Oral contraceptive use in relation to age at menopause in the DOM cohort. Hum 
Reprod 2001; 16:1657-1662. 
23. Adamopoulos DA, Karamertzanis M, Thomopoulos A, Pappa A, Koukkou E, Nicopoilou 
SC.  Age at menopause and prevalence of its different types in contemporary Greek 
women. Menopause 2002; 9: 443-448. 
24. Gold EB, Crawford SL, Avis NE, et al. Factors related to age at natural menopause: 
longitudinal analyses from SWAN. Am J Epidemiol 2013; 178: 70-83. 
25. Torgerson DJ, Avenell A, Russell IT, Reid DM. Factors associated with onset of 
menopause in women aged 45-49. Maturitas 1994; 19:83-92. 
26. Lawlor DA, Ebrahim S, Smith GD. The association of socioeconomic position across 
the life course and age at menopause: the BritishWomen’s Heart and Health Study. 
BJOG 2003; 110:1078-1087. 
27. Hardy R, Kuh D. Social and environmental conditions across the life course and age at 
menopause in a British birth cohort study. BJOG 2005; 112:346-354. 
28. Kinugawa C, Murakami T, Okamura K, Yajima A. Telomerase activity in normal ovaries 
and premature ovarian failure. Tohoku J Exp Med 2000; 190:231-238. 
29. Hardy R, Kuh D. Menopause and gynaecological disorders: a life course perspective. In: 
Kuh D, Hardy R, editors. A Life Course Approach to Women’s Health. Oxford, UK: 
Oxford University Press; 2002. pp. 64-85. 
30. Mishra GD, Pandeya N, Dobson AJ, et al. Early menarche, nulliparity and the risk for 
premature and early natural menopause. Hum Reprod 2017; 32:679-686. 
31. Sievert LL, Murphy L, Morrison LA, Reza AM, Brown DE. Age at menopause and 
determinants of hysterectomy and menopause in a multi- ethnic community: The Hilo 
Women’s Health Study. Maturitas 2013; 76: 334-341. 
32. Mattison DR, Thorgierssen SS. Smoking and industrial pollution and their effects on 
menopause and ovarian cancer. Lancet 1978; 1:187-188. 
33. Hyland A, Piazza K, Hovey KM, et al. Associations between lifetime tobacco exposure 
with infertility and age at natural menopause: the Women’s Health Initiative 
Observational Study. Tob Control 2016; 25: 706-714. 
34. Kinney A, Kline J, Levin B. Alcohol, caffeine and smoking in relation to age at 
menopause. Maturitas 2006; 54:27-38. 
35. Cooper GS, Baird DD, Darden FR. Measures of menopausal status in relation to 
demographic, reproductive, and behavioral characteristics in a population-based study of 
women aged 35-49 years. Am J Epidemiol 2001; 153:1159-1165. 
36. Dorjgochoo T, Kallianpur A, Gao YT, et al. Dietary and lifestyle predictors of age at 
natural menopause and reproductive span in the Shanghai Women’s Health Study. 
Menopause 2008; 15:924-933. 
37. Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. Association of diet and other 
lifestyle with onset of menopause in Japanese women. Maturitas 1998; 29:105-113. 
38. Nagel G, Altenburg HP, Nieters A, Boffetta P, Linseisen J. Reproductive and dietary 
determinants of the age at menopause in EPIC Heidelberg. Maturitas 2005; 52:337-347. 
39. Mikkelsen TF, Graff-Iversen S, Sundby J, Bjertness E. Early menopause, association 
 53  
with tobacco smoking, coffee consumption and other lifestyle factors: a cross-sectional 
study. BMC Pub Heal 2007; 7:149. 
40. Taneri, P.E., Kiefte-de Jong, J.C., Bramer, W.M., Daan, N.M., Franco, O.H. and Muka, 
T., 2016. Association of alcohol consumption with the onset of natural menopause: a 
systematic review and meta-analysis. Hum Reprod update. 2016; 22:516-528. 
41. Reichman ME, Judd JT, Longcope C, et al. Effects of alcohol consumption on plasma 
and urinary hormone concentrations in premenopausal women. J Natl Cancer Inst 
1993; 85:722-727. 
42. Akahoshi M, Soda M, Nakashima E, et al. The effects of body mass index on age at 
menopause. Int J Obes Relat Metab Disord 2002; 26:961-968. 
43. Forney JP, Milewich L, Chen GT, et al. Aromatization of androstenedione to estrone 
by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and 
endometrial neoplasia. J Clin Endocr Metab 1981; 53:192-199. 
44. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on 
conversion of plasma androstenedione to estrone in postmen- opausal women with and 
without endometrial cancer. Am J Obstet Gynecol 1978; 130:448-455. 
45. Dratva J, Zemp E, Staedele P, et al. Variability of reproductive history across the Swiss 
SAPALDIA cohort—patterns and main determinants. Ann Hum Biol 2007; 34:437-453. 
46. Falsetti L, Pasinetti E, Mazzani MD, Gastaldi A. Weight loss and menstrual cycles: 
clinical and endocrinological evaluation. Gynecol Endocrinol 1992; 6:49-56. 
47. Kim JM, Kim TH, Lee HH, Lee SH, Wang T. Postmenopausal hyperten- sion and 
sodium sensitivity. J Menopausal Med 2014; 20:1-6. 
48. Li J, Eriksson M, Czene K, Hall P, Rodriguez-Wallberg KA. Common diseases as 
determinants of menopausal age. Hum Reprod 2016; 31: 2856-2864. 
49. Lim HS, Kim TH, Lee HH, Park YH, Kim JM, Lee BR. Hypertension and results from the 
Korea National Health and Nutrition Examination Survey (2008-2013). Maturitas 2016; 
90:17-23. 
50. de Kat AC, Dam V, Onland-Moret NC, Eijkemans MJ, Broekmans FJ, van der Schouw 
YT. Unraveling the associations of age and menopause with cardiovascular risk factors 
in a large population-based study. BMC Med 2017; 15:2. 
51. Kok HS, van Asselt KM, van der Schouw YT, et al. Heart disease risk determines 
menopausal age rather than the reverse. J Am Coll Cardiol 2006; 47:1976-1983. 
52. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause 
and time since onset of menopause with cardiovascular outcomes, intermediate vascular 
traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 
2016; 1:767-776. 
53. Lee JS, Hayashi K, Mishra G, Yasui T, Kubota T, Mizunuma H. Independent association 
between age at natural menopause and hypercholesterolemia, hypertension, and diabetes 
mellitus: Japan nurses' health study. J Atheroscler Thromb. 2013; 20:161-9. 
54. Bojar I, Gujski M, Raczkiewicz D, Łyszcz R, Owoc J, Walecka I. Estrogen receptor 
alpha polymorphisms, estradiol level, and occurrence of atherosclerosis risk factors in 
healthy postmenopausal women. Med Sci Monit. 2015; 21:970-9. 
55. Cifkova R, Pitha J, Lejskova M, Lanska V, Zecova S. Blood pressure around the 
menopause: a population study. J Hypertens. 2008; 26:1976-82. 
56. Giordano S, Hage FG, Xing D, Chen YF, Allon S, Chen C, et al. Estrogen and 
cardiovascular disease: is timing everything? Am J Med Sci. 2015; 350:27-35. 
 
 54  
Chapter 4 
 
Hormone Therapy Use in the Canadian Longitudinal Study on Aging (CLSA): A Cross-
Sectional Analysis 
 
Abstract 
Objective: To assess the prevalence and factors associated with hormone therapy (HT) use 
among Canadian women.  
Methods: Baseline data from the Tracking cohort of the Canadian Longitudinal Study on Aging 
(CLSA) was used for this analysis. The main outcome was HT use among women aged 45-85 
years, defined as current, past, and never users. Multinomial logistic regression models were 
used to examine the differences between current, past and never HT users in terms of 
sociodemographic, health behavior and health-related variables. 
Results: Overall, 9.5% of the sample reported current use of HT, while 21.9% reported past use. 
The main factors associated with a lower likelihood of current HT use were: older age (>80 y), 
non-white ethnic background, current employment, regular smoking, obesity, and breast cancer. 
By contrast, alcohol consumption, and the presence of allergies or mood disorders were 
positively associated with current HT use.  
Conclusions:  These findings provide a recent national picture of HT use in Canada that may be 
used to inform opportunities for improved physician–patient communication regarding 
menopause management.  
 
Keywords: Menopause, Hormone Therapy, Prevalence, Canada 
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4.1 Introduction 
 
Vasomotor symptoms (VMS), encompassing night sweats and hot flashes, are 
experienced by 80% of women during the menopausal transition1. Recent data suggest that VMS 
persist for a mean duration of 7.4 years2, with over 30% of women experiencing VMS for 10 
years or more2-5. Hormone therapy (HT) is currently the most effective strategy for managing 
VMS. HT contains estrogen, and in women with an intact uterus (i.e. not having undergone 
hysterectomy), it is combined with a progestogen for endometrial protection from hyperplasia6.  
 
 HT use has fluctuated over the past 60 years owing to changes in its risks and benefits. In 
the late 1990s, the prevalence of hormone use exceeded 40% among women aged 50–69 years in 
the US7. In 2002, the Women’s Health Initiative (WHI) trial revealed an increase in thrombotic 
risk and a slight increase in breast cancer risk among older users of oral estrogens and 
progestogens that subsequently contributed to a worldwide reduction in HT use8. Total HT use 
has been declining ever since 2002; from 29.8% to 15.3% in 2004, with these trends persisting 
up to 7 years post WHI9. Due to the WHI study results, prescription behaviors and indications for 
HT changed, except for its beneficial impact on osteoporosis9. In fact, the clinical guidelines at 
the time of this publication recommend HT use for relief of menopausal symptoms while 
individualizing therapy based on clinical factors such as venous thrombosis, breast cancer, stroke 
and coronary heart disease (CHD) risk, as well as the patient’s quality of life priorities10. 
 
Studies that investigated the characteristics of women’s HT use after 2002 remain 
scarce11-15. Younger age, higher educational level, postmenopausal status, African American and 
Hispanic race, and being married have been associated with HT use, however not all of these 
associations are consistent or conclusive11-16. Little research has been done on HT use in 
Canada17, 18, and of those that have, few studies have reported a reduced frequency of HT use 
after 2002.  For example, De et al18, using data from the National Population Health Survey 
(NPHS), showed that total hormone use among women aged 50–69 years was 29.8% at the 
beginning of 2002 but decreased to 15.3% in 2004 after the publication of the WHI findings. 
VMS impair women’s quality of life19, and unmanaged VMS have been linked to physical health 
outcomes including cardiovascular disease (CVD) with studies revealing an association between 
 56  
VMS and CVD risk factors and subclinical CVD20, 21. Most studies in Canada did not examine 
the characteristics of women who use HT. Furthermore, no updated national estimates of the use 
of HT and its types have been published since the WHI era. A more recent description of the 
prevalence of HT use is important to properly understand whether women are abiding by the 
guidelines for HT use. Given the changing landscape of menopause management, this 
information will provide important insight into the use and monitoring trends of HT use. 
Furthermore, identifying the extent to which individual sociodemographic, medical, and 
behavioral characteristics are associated with the use of HT might help reveal ways of improving 
women’s decision making regarding HT. Given the paucity of information that characterizes 
current HT use, this study aims to assess the prevalence and factors associated with HT use 
among Canadian women. 
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4.2 Methods 
Study Design and Sample 
Baseline data from the Tracking cohort (version 3.0) of the Canadian Longitudinal Study 
on Aging (CLSA) was accessed for secondary analysis. In short, the CLSA is a 20 year 
prospective study of 50,000 men and women aged between 45 and 85 years at baseline. 
Launched in 2010, the CLSA aims to provide national-level insight into the behaviors and health 
of adults ages 45 to 85 years at baseline. The study has two categories of participants: i) the 
Tracking cohort who were randomly selected within age and sex strata in each province and 
followed by telephone interview, and; ii) the Comprehensive cohort participants, who had more 
intensive physical measures as well as questionnaire surveys. The Tracking cohort included 
n=21,241 (M: 10406; F: 10835) free-living participants distributed across all 10 provinces.  
Individuals living in long-term care institutions and having cognitive impairment at the time of 
recruitment were excluded at baseline. However, those living in households and transitional 
housing arrangements (e.g., seniors’ residences, in which only minimal care is provided) were 
included. The CLSA study design has been previously described in detail elsewhere22, 23.  
 
Assessment of Outcome   
The main outcome variable was current HT use. Women using HT when interviewed in 
2010-2013 were defined as current users, women who had used HT in the past were labelled as 
past users, while those who had never taken HT were labeled as never users. Current HT use was 
created using the following variables: age at the time of interview, duration of HT use and age at 
initiation of HT use. Women who did not provide complete information to define current use of 
hormone therapy, and whose age at HT initiation was < 40 years were excluded from this 
analysis as it is possible that they confused hormone therapy indicated for menopause with oral 
contraception, or they may have been diagnosed with primary ovarian insufficiency (premature 
menopause)-a rare condition that indicates hormone use at an earlier age than the majority of 
women who experience normal menopause24.  Therefore, out of the 10,835 women enrolled in 
this study, 694 (6.4% of sample) were excluded from the analysis. A previous study based in 
Denmark on women aged 50-59, found a validity of over 70% for self-reported HT use when 
compared with population-based prescription databases58. Lastly, no data were collected 
regarding the presence of VMS, and information regarding the main reasons for using HT. 
 58  
Covariates  
Sociodemographic variables included age at time of interview (<50, 50-59, 60-69, 70-79, 
≥80 years), ethnicity classified as white, aboriginal, and mixed/other, where “other”  included 
non-white ethnic groups such as South Asian, Chinese, Hispanic, Arab, and Black. Additional 
sociodemographic information included highest education level (less than high school, high 
school to some college, Bachelor’s degree or higher), marital status (partner vs. no partner), 
current employment status, and household income in CAD (< 20,000, 20,000-50,000, 50,000-
100,000, 100,000-150,000, >150,000). Lifestyle factors included smoking status (never, former, 
or current), alcohol consumption (never, less than weekly, at least weekly), and frequency of 
leisure time physical activity in the past year (regular vs. non-regular). Those who answered “at 
least once per day,” or “at least once per week,” were considered regular participants, and those 
who answered “at least once per month,” “at least once per year,” or “never” were considered 
non–regular participants of physical activity. Information on health-related variables included 
menopausal status (pre-, natural, or surgical menopause (hysterectomy)), self-reported Body 
Mass Index (BMI: kg/m2), self-reported status of type 2 diabetes, hypertension, cardiovascular 
disorders, mood disorders, anxiety disorders, allergies, and osteoporosis was included. A cut-off 
of 20kg/m2 was used for a BMI of underweight because most of the women in this sample were 
older (45 and over) and so are less likely to be very underweight. Female cancers were also 
measured and included breast, ovarian, and other gynecological cancers such as cervical and 
endometrial cancers.  
 
Statistical Analysis  
The prevalence of HT use was estimated through population weights and examined at the 
national level. Applying the appropriate sample weights to the CLSA data allowed the survey 
data to be representative of the sampled population. Additional analytic details are available at: 
https://www.clsa-elcv.ca/doc/1041. At the bivariate level, differences in the proportion of type of 
HT use, age at initiation, and duration of HT use were assessed among the different levels of HT 
use by chi-square tests. In order to assess the associations of each independent variable with HT 
use, bivariate and multivariable logistic regression models were used, with HT use in its binary 
form (current versus non-current users) as the dependent variable. Odds ratios (OR) and 
confidence intervals (95% CI) were presented for each variable in the model. Given that our aim 
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was to investigate factors associated with “current” HT use and no difference in 
sociodemographic characteristics was observed when “past” and “never” HT users were 
compared, a single pooled category for “non-current” users was created. To examine the 
differences between HT current, past and never users in terms of sociodemographic, lifestyle and 
health related variables, a multinomial logistic regression (MLR) was performed. The latter 
analysis has been preferred to the classical binomial regression analysis, since it enables 
estimates for current use without excluding past users from the analysis, nor does it join never 
and past users13. As a result of the multinomial regression model, two odds ratios were obtained 
for each variable, the first for the likelihood of being a current versus a never HT user and the 
second for the odds of being a past versus a never user. However, results regarding past HT users 
were not shown in table 2, since they were less relevant for the aim of the present analysis and, 
moreover, data for this group of women were not sufficiently reliable due to difficulty in 
elucidating the temporal sequence between HT use start and cessation and many of the variables 
investigated and due to the potential for reverse causality bias13. Inverse probability weights 
(inflation and analytic weights) were used to account for the complex sampling method as per 
the guidelines set by CLSA. STATA version 12.0 was employed for all analyses. Statistical 
significance for all analyses was set at alpha 0.05 for a two-tailed test.  
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4.3 Results 
In total, 854 out of 10,141 (weighted n=6,426,271) women were included with 9.5% 
reporting current use of HT, 21.9% had used it in the past, and 68.6% were never users (results 
not shown). Age 50-54 years at initiation is the most common group for both current and past HT 
users (Table 1). Among current HT users, 45.6% were taking estrogen alone, 35.5% were on 
estrogen plus progesterone, 8% were using progesterone alone and 9.7% reported estrogen use 
via cream or gel. Table 2 highlights the unadjusted odds ratios of current HT use using binomial 
and multinomial analyses.  Both analyses showed that as women aged they were significantly 
less likely to be current HT users. Women who had more than one ethnic background or were 
neither white nor aboriginal were less likely to be current HT users compared to women of a 
white ethnic background in both MLR and BLR (OR=0.43, 95%CI=0.21-0.89) models. In both 
analyses, former smokers, women who drink either at least weekly or less than weekly, who 
practiced physical activity regularly, who reported being naturally menopausal or having had 
surgical menopause, had allergies, or reported having a mood disorder, had a significantly higher 
odds of being a current HT user than their counterparts. On the other hand, women who were 
obese were less likely to report current HT use in both analyses (OR=0.65, 95%CI=0.52-0.80); 
results were similar for women with diabetes (OR=0.71, 95%CI=0.55-0.91). Women who had 
breast cancer were 54 % less likely to be current users compared to never users (OR=0.46, 
95%CI=0.28-0.76), according to the MLR analysis. Results of the BLR analysis were identical to 
that of the MLR.  
 
Table 3 shows the results of the multivariable analyses. The results of the MLR model 
indicate that the frequency of current HT use significantly decreased with increasing age (e.g. 
women >80 years, (OR=0.31 95%CI=0.15-0.63). Women who were of  a non- white ethnic 
background (OR=0.32, 95%CI=0.14-0.73), currently employed (OR=0.76, 95%CI=0.61-0.94), 
current smokers (OR=0.69 , 95%CI=0.49-0.97), obese (OR=0.57 , 95%CI=0.44-0.75), and who 
had breast cancer (OR=0.43 , 95%CI=0.26-0.71) , were significantly less likely to be current HT 
users than their counterparts. On the contrary, women who regularly performed physical activity 
(OR=1.23,95%CI=1.03-1.46), who drank at least weekly (OR=1.94, 95%CI=1.44-2.61) or less 
than weekly (OR=1.51, 95%CI=1.13-2.02), who were post-menopausal (natural or surgical), 
who had any allergies (OR=1.29, 95%CI=1.08-1.54) or any mood disorders (OR=1.86, 
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95%CI=1.50-2.32) had a higher likelihood of being current HT users.  No significant differences 
were observed according to marital status, education level, diabetes, CVD, ovarian cancer, or 
other female cancers, in both multivariable analyses.  
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4.4 Discussion 
 
This study is the first nationally representative study to report on the prevalence and 
correlates of HT use in Canada. Around 10% of 45-85 year olds in the sample reported current 
use of HT.  A non-white ethnic background, current employment, current smoker, obesity, and 
breast cancer were negatively associated with current HT use, whereas alcohol consumption, 
natural or surgical menopause, and the presence of allergies or mood disorders, were positively 
associated with current HT use. These findings provide a new benchmark of HT use in Canada 
and may inform clinicians about women who are not using HT that perhaps should be using it.  
 
Our estimate of current HT use (9.5%) is similar to the prevalence obtained by a recent 
national online survey assessing HT use that was developed by the North American Menopause 
Society (NAMS) Advisory Panel. This survey, administered to 3,725 women who were 
postmenopausal or experiencing the menopause transition, found that 9% of women were current 
HT users25.  The US based National Health and Nutritional Examination Survey (NHANES) 
reported that 11.9% of women aged 40 and older were currently using oral postmenopausal 
hormones in 2002-200326. This estimate was obtained following publication of the WHI results 
in 2002 that indicated that the health risks of estrogen plus a progestogen outweighed its benefits 
among women with an intact uterus27. In 2004, results for the WHI trial of estrogen only among 
women with hysterectomy showed that this intervention was also associated with an elevated 
risk of stroke and pulmonary embolism. It was therefore concluded that each form of 
postmenopausal hormone was unsuitable for chronic disease prevention, with the exception of 
osteoporosis, in healthy women27, 28. As a consequence, the prevalence of current HT use in the 
NHANES continued to decline, and was at 4.7% for any type of HT in 2009–201026.  Our 
estimate was also comparable with that of other countries such as Australia, where Velentzkis et 
al29 showed that 13% of older women were current HT users. Studies from other countries 
including Italy13, Denmark30, as well as Germany, the UK, France and Spain31 reported HT use 
estimates higher (around 16%) than the current sample. It should be noted that differences in user 
patterns and knowledge of HT across continents exist - in addition to differences in cultural 
expectations about menopause, symptom perception, as well as health-care systems – that could 
collectively account for discrepancies in the estimates obtained. In Canada, the use of HT has 
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also undergone some notable changes over the past two decades. The 2006/2007 National 
Population Health Survey (NPHS) highlighted that 13.7% of postmenopausal Canadian women 
were currently taking or had recently taken any type of HT. This decline in HT use rates 
occurred very rapidly, decreasing from a prevalence of 29.8% in 2002 to a prevalence of 15.3% 
in 200418.  Similar findings were also reported among older (above 65) women in Ontario in late 
200217. Although differences in age ranges and survey methods must be taken into account, 
when taken together, these findings suggest that the overall prevalence of HT use in Canadian 
women has somewhat stabilized over the past decade, following an initial rapid fall after 2002.   
 
Use of HT decreased with increasing age, as expected, since many women may have 
begun this therapy to treat VMS during the menopausal transition and discontinued it as 
symptoms resolved post-menopause. Ethnicity was associated with current HT use, whereby 
women of a non-white ethnic background were less likely to use HT. This finding is consistent 
with that of Gerber et al32, and Brett and Reuben12.  No relationship between hormone use, 
marital status, and education level was detected in our study. This is in contrast to other studies 
that describe these factors as correlates of hormone use13, 32-34. These variations in the results 
obtained are likely to be attributed to differences in methods of HT status definition and 
ascertainment, the age range considered, and the sampling frame employed by each study. 
Employment status was also associated with hormone use, where women who were currently 
working had lower odds of currently using HT. Few recent studies13 have examined the link 
between employment and HT use; however, unlike our findings, several studies conducted in the 
1990s found that a current job is an important positive determinant of current HT use35-37. The 
current relationship between occupation and HT use remains unclear and warrants further 
investigation since VMS that occur during the menopausal transition may pose some difficulties 
for women at work, and so HT can help women have a better quality of life at work by 
alleviating these bothersome symptoms. 
 
Previous studies have supported the hypothesis of an overall healthier profile for HT 
users 13, 36 which is in concordance with our finding that current smokers were less likely to be 
HT users while women who exercised regularly were more likely to be current HT users. A 
positive predicting factor of HT use was alcohol consumption. Indeed, VMS are more frequent 
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among alcohol drinkers than non-drinkers38. In fact, recent data from the longitudinal Health and 
Social Support (HeSSup) Study in Finland39 found that moderate or heavy drinkers were over 
30% more likely to initiate HT than light drinkers or abstainers. Body weight has been reported 
as being related to HT use, whereby overweight and obese women being less likely to use HT13, 
33, 37, and the results of the present study corroborate this observation. The impact of body weight 
on the occurrence of VMS during menopause is not clear. Body fat is a supplemental source of 
estrogen because androstenedione (an androgen and precursor of estrogen) is aromatized into 
estrone in adipose tissue41, 42. As a result, body fat may also be considered a protective factor for 
VMS23. Thus, it is thought that women with higher adiposity have higher estrogen concentrations 
than thinner women and therefore, lower odds of developing VMS44. 
 
Several health conditions were associated with HT use. Interestingly, women who 
reported suffering any allergies were more likely to be current HT users than women with no 
allergies.  A paucity of studies have outlined the association between atopy, asthma and HT use. 
Yet, there is evidence that respiratory symptoms and asthma are associated with HT use 
especially among women with a normal or low BMI45. In fact, studies suggest that use of HT 
improves the symptoms of asthma46. The longitudinal Respiratory Health in Northern Europe 
study, an international, multicenter study, found that the risk of new-onset asthma increased by 
more than two times in women in the menopause transition and who were early 
postmenopausal46. Thus, women with reduced respiratory function may be more likely to use HT 
given their declining estrogen levels due to menopause. Sex steroids affect immune regulation, 
with estradiol showing both pro-inflammatory and anti-inflammatory properties 47, which in turn 
might affect the presentation of asthma, wheezing, and allergic sensitization. Further research is 
needed to explain the role of HT use among women with atopy and asthma, as well as the 
intersection of the role of obesity in this relationship. In addition, women with mood disorders, 
such as depression and bipolar disorder, were more likely to use HT. Our results were similar to 
that indicated by Gerber et al32, where women using the US veteran affairs care system with any 
mental health diagnosis were almost two times more likely to use HT. This relationship might be 
explained by the fact that high anxiety levels, depressive symptoms, and perceived stress48, as 
well as negative mood (affect) 49 have been associated with an increased likelihood of VMS. The 
relationship between negative affect and VMS is bidirectional, as VMS also influence mood50. 
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Low estrogen may be a risk factor for developing and maintaining Post Traumatic Stress 
Disorder (PTSD) after traumatic events51. Moreover, VMS can precede, follow, or occur 
concurrently with depression; however, not all women who experience VMS will also 
experience depression52. Thurston et al53 indicated that women who suffered from different 
forms of childhood abuse or neglect were almost two times at a higher odds of having VMS 
during the menopausal transition as well as lower levels of serotonin. Therefore, estrogen 
therapy could positively impact serotonin receptor distribution rendering it a mood regulator54, 55 
which could encourage adherence to hormone therapy by women with mood disroders55.  The 
relationships between negative affect and VMS are not fully understood, and may involve a 
complex interplay between physiologic factors, such as hormones, neurotransmitters, and sleep 
disorders54, and psychological factors, such as personality type49.  
 
Finally, women reporting breast cancer were significantly less likely to currently use HT 
(OR=0.43, 95%CI=0.26-0.71) which is in accordance with previous studies32, 37. It has been 
established that long-term HT use leads to a small increase breast cancer risk 56. Recent data 
suggest that women who initiate HT soon after menopause have a higher breast cancer risk than 
those who start treatment later57.  For this reason, HT use among women with breast cancer is 
not recommended13. Therefore, the prevalence of hormone consumption among women with 
breast cancer would have been expected to be lower than women with no breast cancer. Another 
reason for the low rate of HT use among breast cancer cases may be due to hormonal therapy 
and/or aromatase inhibitors being the protocol treatment42, 56, and the use of drugs such as 
tamoxifen, an estrogen receptor modulator that acts as an estrogen antagonist by competitively 
binding to estrogen receptors on tumors.  
 
Strengths of this study include that it is the first to present a detailed description of the 
patterns of HT use to date in Canada. Second, use of a large and nationally representative sample 
increases the generalizability of our findings. Furthermore, the number and variety of different 
sociodemographic, health behavior, and other variables controlled for in analysis limits the 
potential for confounding bias. Nonetheless, a few limitations exist. First, the potential for 
reverse causality in some variables is probable; for example, some women might chose to start 
exercising after initiating HT. Second, the cross-sectional nature of the study precludes the 
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inference of causality. Due to the self-report nature of HT use, recall and reporting bias may also 
be present. The percentage of ethnic diversity in the CLSA is relatively low, therefore our results 
can mostly be generalized to whites. Lastly, some associations such as the relationship between 
allergy and HT use may have arisen due to chance, given that many variables were examined in 
the multivariable model.  
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4.5 Conclusion 
 
Results of the present study on a large sample of Canadian adult females estimated that 
current HT use is 9.5%. On the whole, the likelihood of current HT use increased with an overall 
healthier profile than never HT use.  The main factors associated with current HT use were older 
age, a non-white ethnic background, current employment, smoking, alcohol consumption, 
obesity, and the presence of allergies, mood disorders, and breast cancer. Prospective, 
longitudinal studies will better inform our understanding of HT use over time. Mixed methods 
designs examining women’s experience of VMS, as well as decision- making around HT use and 
discontinuation, could help explain the rates found in this study. Ascertainment of providers’ 
knowledge and prescribing patterns will also yield key information to understand HT use, as it is 
important that HT be given after a thorough and systematic risk/benefit assessment.  Finally, 
effective doctor patient communication and programs to increase women’s awareness and 
education about menopause management are essential to improve women’s understanding, 
compliance, and ability to cope with the symptoms accompanying the menopausal transition.
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Table 4.1:  Distribution of hormone therapy (HT) use characteristics in the sample. 
                   HT use 
Age at HT initiation Total 
Sample 
N 
 
 %a 
Past* 
N 
 
%b 
Current* 
N 
 
%b 
P-value 
 <45 years 300,560 4.40 374 16.8 106 11.9 <0.001 
 45-49 years 632,740 9.30 712 32.0 264 29.8  
50-54 years 747,769 11.0 800 35.9 332 37.4  
 >54 years 360,146 5.30 343 15.4 185 20.9  
HT use duration        
 <1 year 580,172 24.7 666 28.1 204 21.5 <0.001 
 1-4 years 508,942 21.7 534 22.4 226 24.0  
 5-9 years 460,231 19.6 555 23.3 174 18.4  
 >9 years 796,565 34.0 624 26.2 342 36.2  
HT type        
 Estrogen and progesterone 725,126 35.5 762 37.9 301 33.4 <0.001 
 Estrogen  932,549  45.6 967 48.1 346 38.4  
 Progesterone 163,695 8.00 131 6.50 84 9.30  
 Estrogen cream or gel applied to skin 197,350 9.70  143 7.10 142 15.8  
 IUD with progesterone 24,882 1.20 8.0 0.40 28 3.10  
a Sample includes never HT users, and is estimated using inflation weights; figures not always sum up to the total 
due to missing values.  
b Frequencies are column percentages estimated using analytic weights. 
* Not including never HT users 
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Table 4.2: Prevalence of HT never, past and current users by various variables and results of the 
unadjusted multinomial analysis for current HT use. 
 Nevera Pasta Currenta Currentb  
 % % % Unadjusted OR (95%CI) 
Variables N (%) N (%) N (%)  
Sociodemographic     
Age (years)      
 <50 1,252(17.8) 17(0.8) 80(9.0) 1.00 
 50-59  3,097(44.1)  332(14.9) 430(48.5) 2.18(1.61-2.94) 
 60-69  1,502(21.4) 1,033(46.4) 265(29.9) 2.77(2.04-3.77) 
 70-79 798(11.4) 684(30.7) 95(10.8) 1.88(1.32-2.66) 
 ≥80 377(5.4) 163(7.3) 16(1.8) 0.67(0.39-1.15) 
Ethnicity       
  White(non-aboriginal) 6,356(92.5) 2,127(96.7) 830(94.4) 1.00 
   Aboriginal 238(3.5) 46(2.1) 37(4.2) 1.31(0.87-1.98) 
  Mixed/other 274(4.0) 26(1.2) 13(1.4) 0.43(0.21-0.89) 
Marital Status      
 With partner 4771(67.9) 1413(63.4) 603(68.0) 1.00 
 No partner 2255(32.1) 816(36.6) 283(32.0) 1.01(0.85- 1.19) 
Education Level      
   Less than high school 514(7.3) 181(8.1) 63 (7.1) 1.00 
   High school to some college 4,069(57.9) 1354(60.8) 508 (57.5) 1.02(0.77-1.36) 
   Bachelor’s degree or higher 2,440(34.7) 692(31.1) 314 (35.5) 1.05(0.78-1.42) 
Employment Status      
   Not currently working 3,441(49.0) 1,852(83.1) 502 (56.6) 1.00 
   Currently working 3,584(51.0) 376(16.9) 385 (43.4) 0.74(0.63-0.86) 
Household Income (CAD)     
 <20,000 447(6.9) 150(7.5) 58 (7.1) 1.00 
 20,000-50,000 1739(26.9) 743(37.0) 179 (22.0) 0.75(0.54-1.03) 
 50,000-100,000 2126(32.9) 764(38.0) 296 (36.3) 1.05(0.77-1.45) 
 100,000-150,000 1239(19.2) 227(11.3) 156 (19.2) 1.10(0.78-1.55) 
 >150,000 916(14.2) 125(6.2) 127(15.5) 1.25(0.87-1.81) 
Lifestyle     
Smoking Status      
   Never 2,582(36.9) 669(30.2) 282(31.9) 1.00 
   Former 3,602(51.5) 1348(60.8) 523(59.1) 1.22 (1.03-1.44) 
   Current 807(11.5) 199(9.0) 79(9.0) 0.90(0.68-1.21) 
 Alcohol consumption      
  Never 1,171(16.7) 352(15.8) 98(11.1) 1.00 
 Drinks less than weekly 2,843(40.5) 792(35.5) 316(35.6) 1.34(1.05-1.72) 
 Drinks at least weekly 3,004(42.8) 1085(48.7) 471(53.2) 1.78(1.40-2.27) 
Leisure time physical activity      
   Non-regular 3,416(48.7) 1,035 (46.6) 373(42.0) 1.00 
   Regular  3,602(51.3) 1,185(53.4) 512(58.0) 1.27(1.09-1.49) 
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Table 4.2(Cont’d): Prevalence of HT never, past and current users by various variables and results 
of the unadjusted multinomial analysis for current HT use. 
Health  related       
Menopause Status       
    No 2,033(29.1) 64 (2.9) 101(11.5) 1.00  
    Natural 4,243(60.6) 1680(75.4) 574(65.4) 2.02(1.56-2.61)  
    Surgical (Hysterectomy) 722(10.3) 486(21.8) 203(23.2) 3.51(2.63-4.67)  
BMI (Kg/m2)      
20.0-24.99 (normal weight) 2,676(38.5) 852(38.5) 362(41.0) 1.00  
<20.00 (underweight) 425(6.1) 110(4.95) 61 (6.9) 1.12(0.80-1.57)  
25.0-29.9 (overweight) 2,110(30.3) 732(33.1) 310 (35.1) 1.06(0.89-1.27)  
> 30.0 (obese) 1,749(25.1) 521(23.5) 151(17.1) 0.65(0.52-0.80)  
Osteoporosis       
    No 6,245(89.2) 1,718(77.4) 766(86.6) 1.00  
    Yes 753(10.8) 503(22.6) 118(13.4) 0.98(0.79 -1.22)  
Hypertension       
   No 4,976(71.0) 1,260(56.6) 614(69.3) 1.00  
   Yes 2,045(29.1) 965(43.4) 272(30.7) 0.92(0.78-1.08)  
Diabetes       
    No  6,105(87.0) 1,888(84.7) 796(90.0) 1.00  
    Yes  915(13.0) 341(15.3) 89(10.1) 0.71(0.55-0.91)  
Cardiovascular disease      
    No  6,434(91.8) 1,922(86.5) 819(92.8) 1.00  
    Yes  577(8.2) 301(13.6) 63(7.2) 0.74(0.56-0.97)  
Breast cancer      
    No 6,678(95.1) 2,082(93.4) 864(97.5) 1.00  
    Yes 348 (4.9) 146(6.6) 22(2.5) 0.46(0.28-0.76)  
Ovarian cancer      
    No 6,989(99.5) 2,207(99.0) 880(99.3) 1.00  
    Yes 37(0.5) 22(0.9) 6 (0.7) 1.20(0.48-2.60)  
Other female cancers      
    No 6,887(98.0) 2,165(97.1) 863(97.4) 1.00  
    Yes 139 (2.0) 63(2.9) 23(2.6) 1.19(0.68 -2.07)  
Allergies      
  No 4,009(57.2) 1,195(53.7) 436(49.3) 1.00  
  Yes 2,999(42.8) 1,030(46.3) 449(51.0) 1.33(1.14-1.55)  
Mood Disorders       
   No 5,906(84.1) 1,794(80.5) 656(74.0) 1.00  
   Yes 1,115(15.9) 434(19.5) 230(26.0) 1.75(1.46-2.09)  
Anxiety Disorders       
    No 6,417(91.4) 2,017(90.6) 790(89.2) 1.00  
    Yes 601(8.6) 209(9.4) 95(10.8) 1.25 (0.98-1.61)  
 a Frequencies are column percentages  estimated using analytic weights. 
b Multinomial logistic regression model predicting HT current vs. never use: odds ratio >1 indicates a higher likelihood of 
being a current HT user, results of past vs. never use are not shown. 
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Table 4.3: Results of the adjusted multinomial logistic analysis for current HT use. 
 Current a 
 Adjusted OR (95%CI) 
Variables  
Sociodemographic  
Age (years)   
<50 1.00 
50-59 1.28(0.86-1.90) 
60-69 1.32(0.83-2.10) 
70-79 0.87(0.52-1.45) 
≥80 0.31(0.15-0.63) 
Ethnicity    
  White (non-aboriginal) 1.00 
   Aboriginal 0.96(0.60-1.52) 
  Mixed/other 0.32(0.14-0.73) 
Marital Status   
With partner 1.00 
No partner 0.81(0.65-1.01) 
Education Level   
   Less than high school 1.00 
   High school to some college 1.08(0.79-1.47) 
   Bachelor’s degree or higher 1.02(0.73-1.42) 
Employment Status   
   Not currently working 1.00 
   Currently working 0.76(0.61-0.94) 
Household Income (CAD)  
<20,000 1.00 
20,000-50,000 0.82(0.57-1.18) 
50,000-100,000 1.15(0.78 -1.69) 
100,000-150,000 1.15(0.74-1.80) 
>150,000 1.41(0.87-2.29) 
Lifestyle  
Smoking Status   
   Never 1.00 
   Former 1.11(0.92-1.34) 
   Current 0.69(0.49-0.97) 
 Alcohol consumption   
Never 1.00 
Drinks less than weekly 1.51(1.13-2.02) 
Drinks at least weekly 1.94(1.44-2.61) 
Leisure time physical activity   
    Non-regular 1.00 
    Regular  1.23(1.03-1.46) 
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Table 4.3 (Cont’d): Results of the adjusted multinomial logistic analysis for current HT use. 
Health  related   
Menopause Status   
    No 1.00 
    Natural 3.01(2.11-4.30) 
    Surgical (Hysterectomy) 7.33(5.05-10.6) 
BMI (Kg/m2)  
20.0-24.99 (normal weight) 1.00 
<20.00 (underweight) 1.09(0.74-1.60) 
25.0-29.99 (overweight) 1.05(0.86-1.27) 
> 30.0 (obese) 0.57(0.44-0.75) 
Osteoporosis   
    No 1.00 
    Yes 1.08(0.83-1.39) 
Hypertension   
    No 1.00 
    Yes 1.10(0.90-1.35) 
Diabetes   
    No  1.00 
    Yes  0.84(0.63-1.12) 
Cardiovascular disease  
    No  1.00 
    Yes  0.84(0.61-1.17) 
Breast cancer  
    No 1.00 
    Yes 0.43(0.26-0.71) 
Ovarian cancer  
    No 1.00 
    Yes    1.10(0.40-3.01) 
Other female cancers  
    No 1.00 
    Yes 1.13(0.59-2.14) 
Allergies  
No 1.00 
Yes 1.29(1.08-1.54) 
Mood Disorders   
   No 1.00 
   Yes 1.86(1.50-2.32) 
Anxiety Disorders   
    No 1.00 
    Yes 1.21(0.89-1.64) 
a Multinomial logistic regression model predicting HT current vs. never use: odds ratio >1 indicates a higher 
likelihood of being a current HT user, results of past vs. never use are not shown. 
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Chapter 5 
General Discussion 
 
This dissertation examined the following objectives using data from the Canadian 
Longitudinal Study on Aging (CLSA) and the Coronary Artery Risk Development in Young 
Adults (CARDIA) study: Objective (1): To assess the impact of changes in weight, BMI, and 
waist circumference across time on ANM in a sample of US women. Objective (2): To 
elucidate median ANM and investigate associations between various factors, and ANM 
among Canadian women. Objective (3): To determine the prevalence of HT use and evaluate 
the associations between various factors, and HT use among Canadian women. Below is a 
description of the major findings by chapter. 
 
 5.1 Major Findings 
In chapter 2, baseline WC was associated with a later ANM. Neither absolute nor relative 
changes in anthropometric measures were associated with ANM with one exception. If there was 
more than 5% weight loss since baseline, the hazard for an earlier ANM decreased by 45%. 
Premenopausal hypertension was strongly associated with an earlier ANM, highlighting the 
importance of cardiovascular risk factors on ANM. In chapter 3, median ANM was 51 years. 
Having no partner, low household income and education levels, current and former smoking, and 
cardiovascular disease (CVD) were associated with an earlier ANM, while current employment, 
any alcohol consumption, and obesity were associated with later ANM. Finally, in chapter 4, 
using data from the CLSA, we found that 9.5% of women had reported current HT use. The 
factors negatively associated with current HT use were: older age, non-white ethnic background, 
current employment, regular smoking, obesity, and breast cancer. By contrast, alcohol 
consumption, and the presence of allergies or mood disorders were positively associated with 
current HT use. 
 
5.2 Public Health Implications  
Natural menopause is a complex bio cultural phenomenon with geographic and ethnic 
variations. ANM is a risk factor for a number of chronic conditions. Therefore, understanding its 
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factors help can identify menopausal women who are at high risk for future morbidity. Despite 
increasing evidence of the importance of natural menopause as a sentinel for future health 
outcomes, no research has examined its associations with various socioeconomic, lifestyle and 
clinical factors in the Canadian population. In addition, limited research has accounted for the 
life course aspect of body size in relation to age at menopause. Using a life course framework, 
Chapter 2 provided insight into potential points of intervention during early adulthood which 
could possibly break the series of cardiovascular risks accumulating over time and thus help 
reduce the associated later health outcomes of ANM. This dissertation used novel techniques by 
examining the influence of various factors on HT use and ANM, and has resulted in findings that 
would benefit the fast-growing menopausal population. HT is currently the most effective 
therapy in managing the symptoms that occur during the menopause transition39-41. HT use rates 
have declined in the years after the publication of several randomized trials in older women that 
suggested coronary harm and that the risks involved, such as breast cancer, outweighed any 
benefit. However, important recent statements from the authors of the WHI and the International 
Menopause Society have emerged stating that, after a personalized risk assessment, an 
appropriate HT formulation is safe, and with a more favorable benefit–risk ratio among young 
postmenopausal women44. The landscape of menopause management has changed in the past 20 
years. Therefore, elucidating the prevalence of HT use and the extent to which individual 
sociodemographic, lifestyle, and clinical characteristics are associated with HT use, may inform 
clinicians about women who are not using HT but perhaps should be using it. Indeed, Chapter 4 
showed that women with obesity are less likely to be current HT users. 
 
 Estrogen deficiency promotes metabolic dysfunction predisposing women to MetS and type 
2 diabetes. Given an established relationship between obesity and CVD risk factors, estrogen’s 
effect on both of these processes is of importance in menopause treatment. In fact, large 
randomized controlled trials have suggested that HT reduces incidence of type 2 diabetes in 
women63, 64, and as a consequence, might reduce CVD risk. Promoting early preventive 
strategies for weight management and clinical monitoring of cardiovascular risk factors for 
women in the menopause transition constitute an important point of intervention for reducing 
future CVD burden65. Smoking is also a strong predictor of early natural menopause, as shown in 
chapter 2. Reducing early menopause by eliminating smoking could provide an additional 
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benefit from smoking cessation, although there is no available evidence that smoking cessation 
extends menopausal age. Our findings further provided evidence that CVD and hypertension 
account for an earlier ANM, as seen in chapters 2 and 3. It is possible that CVD risk early in life 
contributes to both early menopause and CVD via similar mechanisms. Trajectories of 
cardiovascular risk factors (such as cholesterol, weight, and blood pressure) measured during the 
pre-menopause have been associated with the timing of subsequent natural menopause in one 
study66. Using a life course framework, the effect of body size at early adulthood affected ANM. 
As a result, we also provided insight into potential points of intervention specifically during early 
adulthood and which could possibly break the series of risks accumulating over time and thus 
reduce the associated health effects of ANM.  Accordingly, the findings of the current 
dissertation fill an important gap in the literature. 
 
5.3 Limitations 
There are a few limitations in the three analyses that are worth noting. The cross-sectional 
nature of the CLSA study precludes inference of causality. Second, the potential for reverse 
causality in some variables is probable; for example, some women might choose to start 
exercising after initiating HT. Recall bias due to self-report of HT use as well as ANM might 
also be another limitation. Also, the exclusion of women with surgical menopause might affect 
the generalizability of findings. Second, the self-selected nature of participants in the CARDIA, 
as well as the exclusions made for the present analysis might limit generalizability of findings. 
The data were also subject to right censoring because participants had “survived” (not yet 
postmenopausal). However, our analyses accounted for entry at ages 40 years and higher.  
 
5.4 Strengths 
 This dissertation leveraged two existing national, large datasets with a wealth of information 
on important risk factors for ANM and HT use. Strengths include that the second and last 
analyses were the first to present a detailed description of HT use and ANM in Canada. In 
addition, use of a large and nationally representative sample from the CLSA Tracking Cohort 
allowed generalizability of our findings to the majority of the Canadian population. Furthermore, 
the simultaneous adjustment of multiple factors in the Cox model, while censoring at age of HT 
initiation, limited the potential for confounding bias. There were repeated measures on health-
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related risk factors in the CARDIA which were accordingly modeled as time-varying covariates. 
Moreover, availability of data (CARDIA) with over a decade of follow-up provided a unique 
opportunity to understand the associations between earlier life course body size and age at 
menopause in mid-life, since its design helps establish temporality between exposure and 
outcome.  
 
 5.5 Future Research Directions 
First, longitudinal analysis of the CLSA tackling the same objective in Chapter 3 is 
needed to confirm the findings obtained. Stratification of BMI by obesity classes may show 
different associations with ANM and so warrant further investigation. In light of the importance 
of cardiovascular risk factors in the pathway to ANM, as shown in this research, future studies 
should plan to examine inflammatory markers and subclinical measures of CVD, such as carotid 
intima media thickness (ideally with repeated measurements to assess change across time) and 
changes in sex hormone levels as pathways between menopause onset and cardiovascular health 
and mortality later in life. This research would provide further insight into the timing of 
interventions needed during this period and help translate epidemiologic data into effective 
policies and solutions. Additional prospective studies on dietary factors such as fat and protein 
intake and ANM are necessary to provide a conclusive answer on their relationship. Studies are 
required to determine the causal association between CVD, as well as the mediating role of 
lifestyle factors, such as physical activity and alcohol use, and type of menopause and ANM by 
using longitudinal techniques. Future research should aim to prospectively examine the 
prevalence of HT use according to type of HT and menopause type, since our research used cross 
sectional data. The relationships between current employment, alcohol use, and HT use remain 
unclear and warrant further investigation, as Chapter 4 revealed. The role of HT use among 
women with atopy and asthma, as well as the intersection of obesity in this relationship is 
unclear, since this gap has emerged in our results. Finally, more work addressing similar research 
questions as this dissertation among minority or socially disadvantaged groups, such as 
Indigenous peoples, while also accounting for the role of sex hormones, is needed to replicate 
our findings. 
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5.6 Conclusion 
With the increase in life expectancy, the proportion of postmenopausal life also increases.  
ANM is critical for a woman’s health trajectory, as it is an indicator of ovarian function and 
aging. Our results highlighted that menopausal age is associated with modifiable factors. 
Findings might inform prevention strategies that benefit many women going through the 
menopausal transition, highlighting the importance of both control and prevention of 
cardiovascular risk factors, especially blood pressure, in adulthood prior to menopause when 
cardiovascular risk factors are prone to change. Its findings may also be used to inform 
opportunities for improved physician–patient communication regarding menopause management, 
and help in risk assessment, prevention and early management of chronic disease risk during the 
menopausal transition. Therefore, the need for primary and secondary prevention of 
cardiovascular risk factors among women at midlife is a pressing one. Menopause may represent 
a state that requires clinical recognition and specific appropriate treatment. The increased risks of 
HT demonstrated in the WHI had profound effects on clinical practice. Therefore, ensuring that 
practicing clinicians and trainees are equipped with current evidence on menopause management 
and available treatment options is integral to individualizing treatment. Policies stating that 
physicians completing residencies in areas related to menopause receive core competencies and 
updates on treatment modes need to be developed and implemented. Moreover, it is important 
for women to share in decision-making about their symptom management while having the 
support of a healthcare system that is also well-informed on all aspects of this stage in their lives.  
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Appendix A: 
 
In the stphtest command, the proportionality of the model as a whole is tested, and by using 
the detail option, a test of proportionality for each predictor is obtained. If the tests in the table 
are not significant, then proportionality cannot be rejected and there is no violation of the 
proportional assumption.  By using the plot option a graph of the scaled Schoenfeld assumption 
can be obtained. A horizontal line in the graphs is further indication that there is no violation of 
the proportionality assumption. The assumption of proportional hazards for each analysis was 
checked both by inspection plots and Schoenfeld residuals, which did not indicate violation of 
the assumption.  
 
PH assumption tests examples, CARDIA: 
quietly stcox race educ inc smk wrk pa bmi bmibaseline glu logins diabet htn sbp dbp trg ldl hdl 
chol hchol logbn_tfat logbn_carbo logbn_prot , schoenfeld(sch*) scaledsch(sca*) 
stphtest, detail 
                                                                      
      global test                       30.79       22         0.1005
                                                                      
      logbn_prot        -0.03177         0.81        1         0.3672
      logbn_carbo       -0.00171         0.00        1         0.9652
      logbn_tfat         0.06177         2.57        1         0.1087
      hchol             -0.01541         0.16        1         0.6920
      chol               0.01679         0.20        1         0.6541
      hdl               -0.01530         0.17        1         0.6829
      ldl               -0.01704         0.21        1         0.6491
      trg               -0.01323         0.12        1         0.7245
      dbp                0.07755         4.78        1         0.0289
      sbp               -0.07017         3.55        1         0.0596
      htn                0.02638         0.47        1         0.4943
      diabet            -0.01191         0.10        1         0.7525
      logins             0.06884         3.35        1         0.0674
      glu               -0.02936         0.48        1         0.4904
      bmibaseline        0.05564         2.35        1         0.1251
      bmi               -0.06667         3.20        1         0.0735
      pa                 0.04915         1.75        1         0.1862
      wrk                0.01036         0.07        1         0.7902
      smk               -0.07280         3.80        1         0.0513
      inc                0.00083         0.00        1         0.9828
      educ               0.01162         0.09        1         0.7633
      race               0.07937         4.86        1         0.0276
                                                                      
                          rho            chi2       df       Prob>chi2
                                                                      
      Time:  Time
      Test of proportional-hazards assumption
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quietly stcox race educ inc smk wrk pa  wgt wgtbaseline glu logins diabet htn sbp dbp trg ldl hdl chol 
hchol logbn_tfat logbn_carbo logbn_prot , schoenfeld(sch*) scaledsch(sca*) 
stphtest, detail 
 
                                                                      
      global test                       30.79       22         0.1005
                                                                      
      logbn_prot        -0.03177         0.81        1         0.3672
      logbn_carbo       -0.00171         0.00        1         0.9652
      logbn_tfat         0.06177         2.57        1         0.1087
      hchol             -0.01541         0.16        1         0.6920
      chol               0.01679         0.20        1         0.6541
      hdl               -0.01530         0.17        1         0.6829
      ldl               -0.01704         0.21        1         0.6491
      trg               -0.01323         0.12        1         0.7245
      dbp                0.07755         4.78        1         0.0289
      sbp               -0.07017         3.55        1         0.0596
      htn                0.02638         0.47        1         0.4943
      diabet            -0.01191         0.10        1         0.7525
      logins             0.06884         3.35        1         0.0674
      glu               -0.02936         0.48        1         0.4904
      bmibaseline        0.05564         2.35        1         0.1251
      bmi               -0.06667         3.20        1         0.0735
      pa                 0.04915         1.75        1         0.1862
      wrk                0.01036         0.07        1         0.7902
      smk               -0.07280         3.80        1         0.0513
      inc                0.00083         0.00        1         0.9828
      educ               0.01162         0.09        1         0.7633
      race               0.07937         4.86        1         0.0276
                                                                      
                          rho            chi2       df       Prob>chi2
                                                                      
      Time:  Time
      Test of proportional-hazards assumption
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stphtest, plot(dbp) msym(oh) 
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quietly stcox race educ inc smk wrk pa wst wstbaseline glu ins diabet htn sbp dbp trg ldl hdl chol 
hchol logbn_tfat logbn_carbo logbn_prot , schoenfeld(sch*) scaledsch(sca*) 
stphtest, detail 
 
                                                                      
      global test                       30.79       22         0.1005
                                                                      
      logbn_prot        -0.03177         0.81        1         0.3672
      logbn_carbo       -0.00171         0.00        1         0.9652
      logbn_tfat         0.06177         2.57        1         0.1087
      hchol             -0.01541         0.16        1         0.6920
      chol               0.01679         0.20        1         0.6541
      hdl               -0.01530         0.17        1         0.6829
      ldl               -0.01704         0.21        1         0.6491
      trg               -0.01323         0.12        1         0.7245
      dbp                0.07755         4.78        1         0.0289
      sbp               -0.07017         3.55        1         0.0596
      htn                0.02638         0.47        1         0.4943
      diabet            -0.01191         0.10        1         0.7525
      logins             0.06884         3.35        1         0.0674
      glu               -0.02936         0.48        1         0.4904
      bmibaseline        0.05564         2.35        1         0.1251
      bmi               -0.06667         3.20        1         0.0735
      pa                 0.04915         1.75        1         0.1862
      wrk                0.01036         0.07        1         0.7902
      smk               -0.07280         3.80        1         0.0513
      inc                0.00083         0.00        1         0.9828
      educ               0.01162         0.09        1         0.7633
      race               0.07937         4.86        1         0.0276
                                                                      
                          rho            chi2       df       Prob>chi2
                                                                      
      Time:  Time
      Test of proportional-hazards assumption
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Goodness of fit of the model can be evaluated by using the Cox-Snell residuals. If the model 
fits the data well then the true cumulative hazard function conditional on the covariate vector 
has an exponential distribution with a hazard rate of one. This translates into fitting the model 
using the stcox command and specifying the mgale option which will generate the martingale 
residuals.  Then the predict command with the csnell option is employed to generate the Cox-
Snell residuals for the model. The data is reset using the stset command specifying the 
variable cs, the variable containing the Cox-Snell residuals, as the time variable. The sts 
generate command is used to create the Nelson-Aalen cumulative hazard function.  Finally, the 
Nelson-Aalen cumulative hazard function and the cs variable are graphed so that the hazard 
function can be compared to the diagonal line.  If the hazard function follows the 45 degree line 
then it approximately has an exponential distribution with a hazard rate of one and that the 
model fits the data well. Goodness of fit of the multivariate Cox models was assessed using the 
likelihood ratio test and Cox-Snell residuals, which indicated a good overall fit.  
 
Goodness of fit example, CARDIA: 
quietly stcox race educ wrk inc smk drnk bc parity pac wst wstbaseline glu logins diabet htn sbp 
dbp trg ldl hdl chol hchol logbn_tfat logbn_carbo  logbn_prot , nohr mgale(mg) 
predict cs, csnell 
stset cs, failure(failure) 
sts generate H = na 
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) 
 
0
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0 1 2 3 4
Cox-Snell residual
Nelson-Aalen cumulative hazard Cox-Snell residual
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Appendix B: 
 
In the stphtest command, the proportionality of the model as a whole is tested, and by using 
the detail option, a test of proportionality for each predictor is obtained. If the tests in the table 
are not significant, then a violation of the proportional assumption is not 
present. The stphplot command uses log-log plots to test proportionality and if the lines in 
these plots are parallel then we have further indication that the predictors do not violate the 
proportionality assumption. Validity of the proportional hazards assumption was checked by 
log-log plots with most variables not violating the assumption with the exception of: household 
income, smoking status, and CVD status. However, upon close inspection of the plots, the 
curves were close to parallel, with a minimal effect on the interpretation of the results. 
Moreover, based on prior research those variables were important factors, therefore the model 
was left unaltered.  
 
PH assumption test, CLSA: 
quietly stcox eth_fin_white income_rec marital_stat_recoded educ_rec current_wrk smk_status 
alc_freq_recoded sport_part bmi_recoded allergies_rec  htn_rec diab_rec CVD_no anx_rec mooddis_rec , 
schoenfeld(sch*) scaledsch(sca*) 
 stphtest, detail 
                                                                      
      global test                      108.93       15         0.0000
                                                                      
      mooddis_rec        0.01050         0.53        1         0.4684
      anx_rec            0.00153         0.01        1         0.9161
      CVD_no             0.03800         6.74        1         0.0094
      diab_rec          -0.01034         0.50        1         0.4789
      htn_rec           -0.00993         0.46        1         0.4972
      allergies_~c       0.01063         0.53        1         0.4663
      bmi_recoded        0.00418         0.08        1         0.7728
      sport_part         0.01268         0.76        1         0.3835
      alc_freq_r~d       0.01712         1.39        1         0.2378
      smk_status        -0.06034        17.76        1         0.0000
      current_wrk        0.05275        13.35        1         0.0003
      educ_rec           0.03100         4.34        1         0.0373
      marital_st~d      -0.02261         2.41        1         0.1202
      income_rec         0.04037         7.71        1         0.0055
      eth_fin_wh~e       0.00651         0.20        1         0.6547
                                                                      
                          rho            chi2       df       Prob>chi2
                                                                      
      Time:  Time
      Test of proportional-hazards assumption
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stphplot, by(income_rec) legend(off) title(Plot of -log(-log(S(t)))) 
graph export coxphplot.png, width(500) replace 
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stphplot, by(educ_rec) legend(off) title(Plot of -log(-log(S(t)))) 
graph export coxphplot.png, width(500) replace 
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stphplot, by(current_wrk) legend(off) title(Plot of -log(-log(S(t)))) 
graph export coxphplot.png, width(500) replace 
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stphplot, by(smk_status) legend(off) title(Plot of -log(-log(S(t)))) 
graph export coxphplot.png, width(500) replace 
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stphplot, by(CVD_no) legend(off) title(Plot of -log(-log(S(t)))) 
graph export coxphplot.png, width(500) replace 
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Goodness of fit of the model can be evaluated by using the Cox-Snell residuals. If the model 
fits the data well then the true cumulative hazard function conditional on the covariate vector 
has an exponential distribution with a hazard rate of one. This translates into fitting the model 
using the stcox command and specifying the mgale option which will generate the martingale 
residuals.  Then the predict command with the csnell option is employed to generate the Cox-
Snell residuals for the model. The data is reset using the stset command specifying the 
variable cs, the variable containing the Cox-Snell residuals, as the time variable. The sts 
generate command is used to create the Nelson-Aalen cumulative hazard function.  Finally, the 
Nelson-Aalen cumulative hazard function and the cs variable are graphed so that the hazard 
function can be compared to the diagonal line.  If the hazard function follows the 45 degree line 
then it approximately has an exponential distribution with a hazard rate of one and that the 
model fits the data well. Goodness of fit of the multivariate Cox model was also assessed using 
the likelihood ratio test and Cox-Snell residuals to create the Nelson-Aalen cumulative hazard 
function. Our data overall followed an exponential distribution indicating that our model fits the 
data well. 
 
Goodness of fit test, CLSA:  
quietly stcox eth_fin_white marital_stat_recoded educ_rec current_wrk income_rec smk_status alc_freq_recoded 
sport_part bmi_recoded htn_rec allergies_rec diab_rec CVD_no mooddis_rec anx_rec, nohr mgale(mg) 
. predict cs, csnell 
. stset cs, failure(failure) 
sts generate H = na 
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) 
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